[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 140
1. Tadokoro M, Yonese J, Tsukamoto T, Okubo Y, Hanada E, Satoh Y, Nakagawa K, Ishikawa Y, Fukui I: Successful treatment of chemo-refractory pulmonary metastases of renal pelvic cancer by second-line chemotherapy including gemcitabine followed by salvage surgery. Int J Urol; 2005 Feb;12(2):208-10
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of chemo-refractory pulmonary metastases of renal pelvic cancer by second-line chemotherapy including gemcitabine followed by salvage surgery.
  • A 51-year-old woman developed multiple pulmonary metastases after receiving nephroureterectomy and two cycles of adjuvant chemotherapy for the treatment of renal pelvic transitional cell carcinoma.
  • All metastases disappeared after four cycles of methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) chemotherapy followed by radiotherapy; however, 8 months later two pulmonary metastases recurred.
  • The patient was entered into a phase I study of combination chemotherapy with gemcitabine, etoposide and cisplatin, designed for chemorefractory urothelial cancer.
  • The lung masses showed significant reduction after two cycles of this chemotherapy; following salvage surgery, the patient has been well with no evidence of recurrence for more than 3 years.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Drug Resistance, Neoplasm. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Salvage Therapy
  • [MeSH-minor] Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / therapy. Cisplatin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Kidney Neoplasms / pathology. Kidney Neoplasms / therapy. Kidney Pelvis / pathology. Kidney Pelvis / surgery. Middle Aged

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15733118.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6PLQ3CP4P3 / Etoposide; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


2. Pizza G, De Vinci C, Lo Conte G, Mazzuca A, Di Maio V, Ratini S, Severini G, Busutti L, Palareti AP, Gulino A, Vacca A, Melchiorri L, Ferrari M, Giacomelli L, Baricordi OR, Forzini S, Capanna R: Allogeneic gene-modified tumour cells in metastatic kidney cancer. Report II. Folia Biol (Praha); 2004;50(6):175-83
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic gene-modified tumour cells in metastatic kidney cancer. Report II.
  • In a limited study, comprising only ten patients, we have previously reported that allogeneic irradiated RCC-cell-line cells, engineered to produce IL-2 (ACHN-IL-2), admixed with autologous metastatic formalin-treated tumour cells were used to vaccinate MRCC patients in progression of disease and also receiving IL-2 immunotherapy.
  • Throughout this period, the patients continued receiving the previously set immunotherapy treatment.
  • No adverse side effects related to the treatment were noticed.
  • One complete and four partial tumour responses were observed, as well as nine cases of stable disease.
  • Responding patients resumed progression in 4-11 months and died 18 and 36 months after beginning the vaccine therapy.
  • [MeSH-major] Cancer Vaccines / therapeutic use. Carcinoma, Renal Cell / drug therapy. Interleukin-2 / genetics. Kidney Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Treatment Outcome. Vaccination

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15709712.001).
  • [ISSN] 0015-5500
  • [Journal-full-title] Folia biologica
  • [ISO-abbreviation] Folia Biol. (Praha)
  • [Language] eng
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Interleukin-2
  •  go-up   go-down


3. Parsa V, Heilbrun L, Smith D, Sethi A, Vaishampayan U: Safety and efficacy of sorafenib therapy in patients with metastatic kidney cancer with impaired renal function. Clin Genitourin Cancer; 2009 Aug;7(2):E10-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of sorafenib therapy in patients with metastatic kidney cancer with impaired renal function.
  • PURPOSE: Sorafenib is an oral Raf kinase inhibitor, approved for the treatment of advanced renal cancer.
  • Clinical investigation of the safety and feasibility of sorafenib therapy in patients with impaired renal function was performed in this study.
  • Medical records of patients with metastatic renal cancer at Wayne State University started on sorafenib between November 2005 to January 2007 were reviewed.
  • Patients with a calculated creatinine clearance (CrCl) of 60 mL/min or less (chronic kidney disease stage 3 or greater per Kidney Disease Outcomes Quality Initiative guidelines) were deemed to have renal insufficiency.
  • RESULTS: A total of 32 patients who met the selection criteria were analyzed.
  • Fourteen of 32 (44%) patients had renal insufficiency (range, 32-60 mL/min).
  • Incidence of diarrhea (57% vs. 33%) and hand-foot syndrome (86% vs. 56%) were higher in the renal-dysfunction group.
  • Dose interruptions and dose reductions were noted in 57% and 43% of patients with renal dysfunction versus 28% and 22% in those without.
  • CONCLUSION: Renal insufficiency is frequently observed in patients with advanced renal cancer.
  • Sorafenib therapy can be safely delivered in patients with mild and moderate renal dysfunction, and efficacy appears to be maintained.

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] J Clin Oncol. 2004 Feb 1;22(3):454-63 [14752067.001]
  • [Cites] Int Urol Nephrol. 2003;35(2):263-5 [15072507.001]
  • [Cites] Urology. 1998 Feb;51(2):203-5 [9495698.001]
  • [Cites] Kidney Int. 2005 Jun;67(6):2089-100 [15882252.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2505-12 [16636341.001]
  • [Cites] World J Urol. 2006 Aug;24(3):255-66 [16479388.001]
  • [Cites] BJU Int. 2006 Aug;98(2):298-302 [16879668.001]
  • [Cites] Int J Urol. 2006 Aug;13(8):1045-8 [16903927.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] Oncologist. 2007 Apr;12(4):426-37 [17470685.001]
  • [Cites] Cancer Sci. 2008 Jan;99(1):159-65 [17953709.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] N Engl J Med. 2001 Dec 6;345(23):1655-9 [11759643.001]
  • (PMID = 19692316.001).
  • [ISSN] 1938-0682
  • [Journal-full-title] Clinical genitourinary cancer
  • [ISO-abbreviation] Clin Genitourin Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA022453; United States / NCI NIH HHS / CA / CA-22453
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  • [Other-IDs] NLM/ NIHMS514487; NLM/ PMC3865860
  •  go-up   go-down


Advertisement
4. Doehn C: [New drugs for metastatic kidney cancer]. Aktuelle Urol; 2008 Jan;39(1):41-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [New drugs for metastatic kidney cancer].
  • Systemic therapy of metastatic kidney cancer has undergone dramatic changes over the past years.
  • Furthermore, signalling pathways have been identified to be relevant for tumour progression and therapeutic intervention.
  • Until some years ago, systemic therapy for kidney cancer consisted of cytokines.
  • In this review, new drugs for the treatment of metastatic kidney cancer are discussed.
  • These drugs predominantly interact the VEGF, EGFR and mTOR signalling pathways.
  • Four drugs have been studied in phase III trials and were (or will soon be) approved for treatment of metastatic kidney cancer.
  • Additionally, many drugs are currently being tested in phase I and phase II trials.
  • At present, the following scenarios have an impact on therapy decisions: different prognostic groups, first-line and second-line therapy, combination therapies and the impact of different histological subtypes.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Renal Cell / drug therapy. Kidney Neoplasms / drug therapy
  • [MeSH-minor] Clinical Trials, Phase I as Topic. Clinical Trials, Phase II as Topic. Clinical Trials, Phase III as Topic. Cytokines / therapeutic use. Disease Progression. Humans. Immunologic Factors / administration & dosage. Immunologic Factors / therapeutic use. Karnofsky Performance Status. Kidney / pathology. Prognosis. Protein Kinase Inhibitors / administration & dosage. Protein Kinase Inhibitors / therapeutic use. Protein Kinases / drug effects. Receptor, Epidermal Growth Factor / drug effects. Risk Factors. Signal Transduction / drug effects. TOR Serine-Threonine Kinases. Time Factors. Vascular Endothelial Growth Factor A / drug effects


5. Mulamalla K, Truskinovsky AM, Dudek AZ: Pulmonary blastoma with renal metastasis responds to sorafenib. J Thorac Oncol; 2007 Apr;2(4):344-7
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary blastoma with renal metastasis responds to sorafenib.
  • Biphasic pulmonary blastoma is a rare malignancy of the lung composed of proliferating epithelial and mesenchymal cells with a high vessel density at the tumor periphery.
  • We report a rare case of renal metastasis of biphasic pulmonary blastoma that responded to sorafenib, an oral multikinase inhibitor.
  • After 2 months of treatment with sorafenib, the renal tumor size decreased sufficiently to allow a safe laparoscopic radical nephrectomy.
  • [MeSH-major] Benzenesulfonates / administration & dosage. Kidney Neoplasms / drug therapy. Kidney Neoplasms / secondary. Lung Neoplasms / pathology. Pulmonary Blastoma / secondary. Pyridines / administration & dosage
  • [MeSH-minor] Administration, Oral. Adult. Biopsy, Needle. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Immunohistochemistry. Neoplasm Staging. Nephrectomy / methods. Niacinamide / analogs & derivatives. Phenylurea Compounds. Pneumonectomy / methods. Risk Assessment. Treatment Outcome

  • Genetic Alliance. consumer health - Blastoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409808.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


6. Singer EA, Bratslavsky G, Linehan WM, Srinivasan R: Targeted therapies for non-clear renal cell carcinoma. Target Oncol; 2010 Jun;5(2):119-29
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted therapies for non-clear renal cell carcinoma.
  • The treatment of advanced and metastatic kidney cancer has been revolutionized by the development of targeted systemic therapies.
  • Despite the growing number of available agents approved for use against clear cell renal cell carcinoma, patients with non-clear histologies, constituting approximately 1 in 4 cases of kidney cancer, have not received the same attention.
  • The majority of clinical trials testing novel targeted therapies have excluded non-clear subtypes, providing limited therapeutic options for patients with these diagnoses and their oncologists.
  • This review will focus on the use of targeted therapies against the non-clear histologic subtypes of renal cell carcinoma: papillary I and II, chromophobe, and collecting duct.
  • The unique genetic and molecular profiles of each distinct non-clear kidney cancer subtype will be described, as these differences are integral to the development and effectiveness of the novel agents used to treat them.
  • Trials focusing on non-clear kidney cancer, or those that treated clear cell tumors along with significant numbers of non-clear subtypes, will be discussed.
  • The role of cytoreductive nephrectomy and the use of neoadjuvant and adjuvant targeted therapy will be reviewed.
  • [MeSH-major] Carcinoma, Papillary / therapy. Carcinoma, Renal Cell / therapy. Clinical Trials as Topic. Kidney Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Drug Design. Gene Expression Profiling. Humans. Nephrectomy

  • Genetic Alliance. consumer health - Clear Cell Renal Cell Carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1990 Sep;144(3):614-7; discussion 617-8 [2201792.001]
  • [Cites] J Urol. 1992 Jan;147(1):24-30 [1729540.001]
  • [Cites] Science. 1993 May 28;260(5112):1317-20 [8493574.001]
  • [Cites] Urol Clin North Am. 1993 May;20(2):303-21 [8493752.001]
  • [Cites] J Urol. 1995 Mar;153(3 Pt 2):907-12 [7853572.001]
  • [Cites] Nat Genet. 1997 May;16(1):68-73 [9140397.001]
  • [Cites] J Pathol. 1997 Oct;183(2):131-3 [9390023.001]
  • [Cites] Oncogene. 1998 Aug 13;17(6):733-9 [9715275.001]
  • [Cites] J Urol. 1999 Jul;162(1):43-5 [10379736.001]
  • [Cites] N Engl J Med. 2005 Dec 8;353(23):2477-90 [16339096.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):16-24 [16330672.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2516-24 [16757724.001]
  • [Cites] J Korean Med Sci. 2006 Aug;21(4):672-7 [16891811.001]
  • [Cites] Am J Pathol. 1999 Aug;155(2):517-26 [10433944.001]
  • [Cites] Curr Mol Med. 2004 Dec;4(8):855-68 [15579033.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):591-8 [15659506.001]
  • [Cites] Br J Cancer. 2005 Mar 14;92(5):843-6 [15756254.001]
  • [Cites] Oncologist. 2005 Mar;10(3):191-7 [15793222.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2763-71 [15837991.001]
  • [Cites] Am J Hum Genet. 2005 Jun;76(6):1023-33 [15852235.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 15;97(12):931-5 [15956655.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):143-53 [16098467.001]
  • [Cites] Semin Oncol. 2006 Oct;33(5):544-51 [17045083.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):671s-679s [17255292.001]
  • [Cites] J Urol. 2007 May;177(5):1698-702 [17437788.001]
  • [Cites] J Urol. 2007 Jun;177(6):1978-84 [17509276.001]
  • [Cites] Cancer Treat Rev. 2007 May;33(3):299-313 [17329029.001]
  • [Cites] N Engl J Med. 2007 May 31;356(22):2271-81 [17538086.001]
  • [Cites] Clin Cancer Res. 2007 Aug 15;13(16):4667-71 [17699843.001]
  • [Cites] Am J Surg Pathol. 2007 Oct;31(10):1578-85 [17895761.001]
  • [Cites] J Urol. 2007 Nov;178(5):1896-900 [17868729.001]
  • [Cites] J Clin Oncol. 2008 Jan 1;26(1):127-31 [18165647.001]
  • [Cites] Cancer. 2008 Apr 1;112(7):1480-8 [18240184.001]
  • [Cites] Expert Opin Biol Ther. 2008 Jun;8(6):779-90 [18476789.001]
  • [Cites] J Urol. 2008 Jul;180(1):94-8 [18485389.001]
  • [Cites] Curr Opin Urol. 2008 Sep;18(5):474-80 [18670270.001]
  • [Cites] Cancer. 2008 Sep 15;113(6):1324-31 [18661529.001]
  • [Cites] BJU Int. 2008 Sep;102(6):692-6 [18410444.001]
  • [Cites] BJU Int. 2009 Jan;103(2):150-3 [19007359.001]
  • [Cites] Lancet. 2009 Mar 28;373(9669):1119-32 [19269025.001]
  • [Cites] Med Oncol. 2009;26(2):202-9 [19229667.001]
  • [Cites] J Natl Compr Canc Netw. 2009 Jun;7(6):645-56 [19555586.001]
  • [Cites] J Natl Compr Canc Netw. 2009 Jun;7(6):659-65 [19555587.001]
  • [Cites] J Clin Oncol. 2009 Jul 1;27(19):3225-34 [19470934.001]
  • [Cites] Nat Rev Urol. 2009 Jul;6(7):375-83 [19528960.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] J Clin Oncol. 2009 Aug 1;27(22):3584-90 [19487381.001]
  • [Cites] Lancet Oncol. 2009 Aug;10(8):757-63 [19615940.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18722-7 [19850877.001]
  • [Cites] J Clin Oncol. 2009 Dec 1;27(34):5788-93 [19884559.001]
  • [Cites] Annu Rev Med. 2010;61:329-43 [20059341.001]
  • [Cites] Urol Oncol. 2010 Jan-Feb;28(1):69-73 [20123351.001]
  • [Cites] Cancer Invest. 2010 Mar;28(3):312-22 [19863345.001]
  • [Cites] Cancer. 2010 Mar 1;116(5):1272-80 [20082451.001]
  • [Cites] Nat Rev Urol. 2010 May;7(5):277-85 [20448661.001]
  • [Cites] Lancet Oncol. 2010 Jun;11(6):571-8 [20381423.001]
  • [Cites] BJU Int. 2010 Jul;106(2):218-23 [19922542.001]
  • [Cites] Eur Urol. 2009 Dec;56(6):959-71 [19748725.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):425-31 [11208835.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3387-92 [11248088.001]
  • [Cites] Am J Hum Genet. 2001 Oct;69(4):876-82 [11533913.001]
  • [Cites] Lancet. 2001 Sep 22;358(9286):966-70 [11583750.001]
  • [Cites] N Engl J Med. 2001 Dec 6;345(23):1655-9 [11759643.001]
  • [Cites] Nat Genet. 2002 Apr;30(4):406-10 [11865300.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Apr;11(4):393-400 [11927500.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2376-81 [11981011.001]
  • [Cites] Cancer Cell. 2002 Aug;2(2):157-64 [12204536.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1542-52 [12459621.001]
  • [Cites] Oncogene. 2003 Feb 13;22(6):847-52 [12584564.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1214-22 [12663707.001]
  • [Cites] Am J Surg Pathol. 2003 May;27(5):612-24 [12717246.001]
  • [Cites] Lancet. 2003 Jun 14;361(9374):2059-67 [12814730.001]
  • [Cites] J Urol. 2003 Dec;170(6 Pt 1):2163-72 [14634372.001]
  • [Cites] J Urol. 2004 Mar;171(3):1071-6 [14767273.001]
  • [Cites] Histopathology. 1986 Nov;10(11):1131-41 [3542784.001]
  • (PMID = 20680492.001).
  • [ISSN] 1776-260X
  • [Journal-full-title] Targeted oncology
  • [ISO-abbreviation] Target Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / BC / Z01 BC011023-01; United States / NCI NIH HHS / BC / Z01 BC011028-01; United States / NCI NIH HHS / BC / Z01 BC011038-01; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ NIHMS254814; NLM/ PMC3003336
  •  go-up   go-down


7. Sawazaki H, Okasyo K, Takahashi T, Taki Y, Takeuchi H: [Gluteal muscular metastasis from renal pelvic tumor]. Hinyokika Kiyo; 2008 May;54(5):361-3
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gluteal muscular metastasis from renal pelvic tumor].
  • We present a case of gluteal muscular metastasis from a renal pelvic tumor.
  • A 57-year-old man had undergone right nephroureterectomy and received 2 courses of adjuvant chemotherapy (MEC: methotrexate, epirubicin, cisplatin) for invasive renal pelvic tumor.
  • Five months after the operation, computed tomography (CT) revealed pulmonary metastasis and right adrenal gland recurrence.
  • He underwent 2 courses of chemotherapy (gemcitabine, paclitaxel).
  • Since the size of the pulmonary metastasis and right adrenal gland recurrence showed no change, the gluteal mass was excised.
  • Pathological diagnosis was metastatic urothelial carcinoma.
  • Adjuvant chemotherapy (TIN: paclitaxel, ifosfamide, nedaplatin) 3 courses were performed, but postchemotherapy-CT scan showed a new 2.4 cm mass in the right gluteal muscle.
  • He received radiation therapy (total 30 Gy) for the new gluteal mass.
  • The common metastatic sites of renal pelvic tumor are lungs, liver, bone, and lymph nodes.
  • Gluteal muscle is an uncommon site of metastasis of urothelial carcinoma.
  • This is the 1st case of gluteal muscle metastasis from renal pelvic tumor in the literature.
  • [MeSH-major] Buttocks. Carcinoma, Transitional Cell / pathology. Kidney Neoplasms / pathology. Kidney Pelvis. Muscle Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18546862.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


8. Escudier B, Paparel P, Neuzillet Y, Long JA, Rioux-Leclercq N, Correas JM, Lang H, Poissonnier L, Baumert H, Mejean A, Patard JJ: [Treatment of metastatic kidney cancer in elderly subjects]. Prog Urol; 2009 Nov;19 Suppl 3:S129-32
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of metastatic kidney cancer in elderly subjects].
  • [Transliterated title] Traitement du cancer du rein métastatique chez les sujets âgés.
  • Treatment of metastatic kidney cancer in elderly subjects is identical to treatment of younger subjects.
  • Whereas cytokines were classically contraindicated in patients over 70 or 75 years (notably IL2), new targeted therapies have been evaluated and found to be usable with no age limit, and all of the phase III studies have included patients 80 years old and older.
  • As for tolerance, it is satisfactory for all therapies.
  • Given the data available today, no dose adaptation in relation to age is recommended in metastatic renal cancer.
  • [MeSH-major] Kidney Neoplasms / drug therapy. Kidney Neoplasms / pathology
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Humans. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20123496.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


9. Walker PR, Khuder SA, Quan WD Jr: Continuous infusion interleukin-2 and antihistamines in metastatic kidney cancer. Cancer Biother Radiopharm; 2005 Oct;20(5):487-90
Hazardous Substances Data Bank. FAMOTIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Continuous infusion interleukin-2 and antihistamines in metastatic kidney cancer.
  • A prior randomized trial suggested a possible survival advantage favoring the combination of histamine and subcutaneous interleukin-2 (IL-2), compared to IL-2 alone in patients with metastatic melanoma.
  • We sought to determine whether there was any negative effect of the combination in patients with metastatic kidney cancer.
  • High-dose continuous (or constant) infusion (CIV) interleukin-2 was used as the reference therapy because of the relatively constant IL-2 levels generated by this approach.
  • A total of 47 patients responded to therapy.
  • In this study of CIV IL-2 and antihistamines, this combination appears to be active in metastatic kidney cancer.
  • [MeSH-major] Histamine H1 Antagonists / therapeutic use. Interleukin-2 / administration & dosage. Kidney Neoplasms / drug therapy
  • [MeSH-minor] Adjuvants, Immunologic / therapeutic use. Antineoplastic Agents / therapeutic use. Cimetidine / therapeutic use. Famotidine / therapeutic use. Histamine / therapeutic use. Histamine H2 Antagonists / therapeutic use. Humans. Neoplasm Metastasis. Ranitidine / therapeutic use. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. HISTAMINE .
  • Hazardous Substances Data Bank. CIMETIDINE .
  • Hazardous Substances Data Bank. RANITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16248764.001).
  • [ISSN] 1084-9785
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antineoplastic Agents; 0 / Histamine H1 Antagonists; 0 / Histamine H2 Antagonists; 0 / Interleukin-2; 5QZO15J2Z8 / Famotidine; 80061L1WGD / Cimetidine; 820484N8I3 / Histamine; 884KT10YB7 / Ranitidine
  •  go-up   go-down


10. Quan WD Jr, Vinogradov M, Quan FM, Khan N, Liles DK, Walker PR: Continuous infusion interleukin-2 and famotidine in metastatic kidney cancer. Cancer Biother Radiopharm; 2006 Oct;21(5):515-9
Hazardous Substances Data Bank. FAMOTIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Continuous infusion interleukin-2 and famotidine in metastatic kidney cancer.
  • Infusional interleukin-2 (IL-2) is able to elicit lymphokine-activated killer cell (LAK) cytotoxicity against kidney cancer in vitro and in vivo.
  • These patients had a median age of 60 years (range, 29-72), had a median performance status of 1 (range, 0-1), and had metastatic sites, including lung, bone, lymph node, and liver.
  • This combination of infusional IL-2 with famotidine is active in metastatic kidney cancer.
  • [MeSH-major] Famotidine / administration & dosage. Immunotherapy / methods. Interleukin-2 / administration & dosage. Kidney Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Drug Synergism. Female. Humans. Killer Cells, Lymphokine-Activated / drug effects. Killer Cells, Lymphokine-Activated / immunology. Male. Middle Aged. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17105423.001).
  • [ISSN] 1084-9785
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-2; 5QZO15J2Z8 / Famotidine
  •  go-up   go-down


11. Quan WD Jr, Quan FM: High-dose intensity pulse interleukin-2 with famotidine in metastatic kidney cancer. Cancer Biother Radiopharm; 2009 Apr;24(2):181-3
Hazardous Substances Data Bank. FAMOTIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose intensity pulse interleukin-2 with famotidine in metastatic kidney cancer.
  • Lymphokine-activated killer cell (LAK) activity against tumor cell lines may be induced by intravenous (i.v.) interleukin-2 (IL-2).
  • Daily short infusions (pulses) have been developed to decrease toxicity while maintaining the anticancer activity of this agent against kidney cancer.
  • We have treated 12 patients with metastatic kidney cancer, using pulse IL-2 (18 million IU/M(2) i.v.) over 15-30 minutes, preceded by famotidine (20 mg I.V. daily for 5 days) on an oncology inpatient unit.
  • Patient characteristics were as follows: 9 males with a median age of 66 years (range, 48-74), and median Eastern Cooperative Oncology Group performance status of 1; common metastatic sites included in the lungs 9 and lymph nodes 3.
  • Pulse IL-2 with famotidine shows activity in kidney cancer.
  • [MeSH-major] Famotidine / administration & dosage. Histamine H2 Antagonists / adverse effects. Histamine H2 Antagonists / therapeutic use. Interleukin-2 / administration & dosage. Kidney Neoplasms / drug therapy
  • [MeSH-minor] Aged. Cytokine-Induced Killer Cells / drug effects. Cytokine-Induced Killer Cells / immunology. Disease Progression. Drug Administration Schedule. Drug Interactions. Female. Humans. Lymphocytes / drug effects. Lymphocytes / metabolism. Male. Middle Aged. Neoplasm Metastasis. Receptors, Interleukin-2 / metabolism. Treatment Outcome

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19409039.001).
  • [ISSN] 1557-8852
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histamine H2 Antagonists; 0 / Interleukin-2; 0 / Receptors, Interleukin-2; 5QZO15J2Z8 / Famotidine
  •  go-up   go-down


12. Quan W Jr, Ramirez M, Taylor C, Vinogradov M, Quan F, Khan N: High-dose continuous infusion plus pulse interleukin-2 and famotidine in metastatic kidney cancer. Cancer Biother Radiopharm; 2005 Feb;20(1):36-40
Hazardous Substances Data Bank. FAMOTIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose continuous infusion plus pulse interleukin-2 and famotidine in metastatic kidney cancer.
  • High-dose continuous infusion interleukin-2 (IL-2) regimens generate a higher degree of lymphokine activated killer cell (LAK) cytotoxicity when tested against tumor cells in vitro and a higher rebound lymphocytosis in vivo than do bolus IL-2 regimens.
  • Lymphocytes initially activated by continuous infusion IL-2 have increased cytotoxicity against cancer cells when they are subsequently pulsed with additional IL-2.
  • Six patients with kidney cancer have been treated with a combination of famotidine 20 mg intravenous bid and continuous infusion IL-2 (18 MIU/sq m/24 hours) for 72 hours, followed by a 24-hour rest, then IL-2 18 MIU/sq m over 15-30 minutes.
  • The most common metastatic sites were the lung, lymph node, and bone.
  • There were no treatment-related deaths, and no patients required intensive care admission.
  • The combination of high-dose continuous infusion plus pulse IL-2 and famotidine is active in metastatic kidney cancer.
  • [MeSH-major] Famotidine / administration & dosage. Interleukin-2 / administration & dosage. Kidney Neoplasms / drug therapy. Killer Cells, Lymphokine-Activated / cytology
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / pharmacology. Combined Modality Therapy. Female. Histamine H2 Antagonists / pharmacology. Humans. Immunotherapy, Adoptive / methods. Male. Middle Aged. Neoplasm Metastasis. Time Factors

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15778577.001).
  • [ISSN] 1084-9785
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Histamine H2 Antagonists; 0 / Interleukin-2; 5QZO15J2Z8 / Famotidine
  •  go-up   go-down


13. Quan WD Jr, Walker PR, Quan FM, Ramirez M, Elsamaloty HM, Ghai V, Vinogradov M, Liles DK: Activity of continuous infusion plus pulse interleukin-2 with famotidine in patients with metastatic kidney cancer or melanoma previously treated with interleukin-2. Cancer Biother Radiopharm; 2006 Oct;21(5):437-42
Hazardous Substances Data Bank. FAMOTIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activity of continuous infusion plus pulse interleukin-2 with famotidine in patients with metastatic kidney cancer or melanoma previously treated with interleukin-2.
  • Lymphokine-activated killer (LAK) cells generated by high-dose continuous infusion interleukin-2 (IL-2) are able to nonspecifically lyse melanoma and kidney cancer cells.
  • In vitro famotidine enhances cytotoxicity of LAK against tumor cells, possibly by increasing IL-2 uptake at the IL-2 receptor on lymphocytes.
  • Second-line therapy is, therefore, needed.
  • We treated 11 patients (6 with metastatic melanoma; 5 having metastatic kidney cancer) who had previously experienced progressive disease on prior IL-2 regimens, with a combination of famotidine 20 mg intravenously (i.v.) twice per day and continuous-infusion IL-2 18 MIU/M2/24 hours x 72 hours, followed 24 hours later by a pulse IL-2 dose (18 MIU/M2 over 15 minutes).
  • Patient characteristics were: 9 males, median age 63 years (range, 57-75), median Eastern Cooperative Oncology Group (ECOG) performance status: 1; most common metastatic sites: lungs, lymph nodes, and soft tissue/subcutaneous (s.c.
  • Five (5) patients (3 with melanoma, 2 with kidney cancer) have had partial responses.
  • Two (2) patients with kidney cancer have been converted to complete responders with resection of residual disease, remaining without relapse at 5+ and 20+ months.
  • This combination has activity in patients with metastatic kidney cancer or melanoma who have received prior IL-2.
  • [MeSH-major] Famotidine / administration & dosage. Immunotherapy / methods. Interleukin-2 / administration & dosage. Kidney Neoplasms / therapy. Melanoma / therapy
  • [MeSH-minor] Aged. Drug Administration Schedule. Drug Synergism. Female. Humans. Infusions, Intravenous. Killer Cells, Lymphokine-Activated / drug effects. Killer Cells, Lymphokine-Activated / immunology. Male. Middle Aged. Neoplasm Metastasis


14. Ko YJ, Atkins MB: Chemotherapies and immunotherapies for metastatic kidney cancer. Curr Urol Rep; 2005 Feb;6(1):35-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapies and immunotherapies for metastatic kidney cancer.
  • Most patients who develop kidney cancer are effectively treated with a radical nephrectomy; however, for those patients who present with or develop metastatic disease, the therapeutic options are limited.
  • Interferon and interleukin-2 remain the standard therapies.
  • Although cytotoxic chemotherapy continues to have a minor role in patients with clear cell renal carcinoma, it may become the treatment of choice for some patients with variant renal cancers.
  • Novel agents targeting the vascular endothelial growth factor, its receptor, and other hypoxia-induced proteins are showing great promise and soon may expand the therapeutic options for patients with advanced kidney cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Immunosuppressive Agents / therapeutic use. Kidney Neoplasms / drug therapy. Kidney Neoplasms / secondary
  • [MeSH-minor] Clinical Trials, Phase III as Topic. Female. Humans. Immunotherapy / methods. Interferons / therapeutic use. Interleukins / therapeutic use. Male. Neoplasm Staging. Prognosis. Randomized Controlled Trials as Topic. Risk Assessment. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1992 Jul;10(7):1119-23 [1607917.001]
  • [Cites] Hematol Oncol Clin North Am. 2002 Oct;16(5):1173-87 [12512388.001]
  • [Cites] N Engl J Med. 2001 Dec 6;345(23 ):1655-9 [11759643.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4641-52 [14581333.001]
  • [Cites] J Clin Oncol. 1991 May;9(5):832-6 [2016626.001]
  • [Cites] J Urol. 2003 Oct;170(4 Pt 1):1141-5 [14501711.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(12):2419-26 [10856102.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] J Clin Oncol. 1991 Apr;9(4):694-704 [2066765.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4082-5 [7513432.001]
  • [Cites] Br J Cancer. 2001 Sep 28;85(7):953-8 [11592764.001]
  • [Cites] Lancet. 2001 Sep 22;358(9286):966-70 [11583750.001]
  • [Cites] J Immunother Emphasis Tumor Immunol. 1993 Feb;13(2):122-9 [8318497.001]
  • [Cites] Urology. 2001 Dec;58(6):1058 [11744492.001]
  • [Cites] J Biol Response Mod. 1990 Dec;9(6):529-37 [2074439.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):302-6 [11773183.001]
  • [Cites] Lancet. 1999 Jan 2;353(9146):14-7 [10023944.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):289-96 [11773181.001]
  • [Cites] Cancer J Sci Am. 1997 May-Jun;3(3):157-62 [9161781.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):688-96 [7884429.001]
  • [Cites] N Engl J Med. 2003 Jul 31;349(5):427-34 [12890841.001]
  • [Cites] J Clin Oncol. 1999 Sep;17 (9):2859-67 [10561363.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):802-11 [12576453.001]
  • [Cites] J Urol. 1992 Jan;147(1):24-30 [1729540.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):909-18 [14990647.001]
  • [Cites] J Urol. 1997 Nov;158(5):1691-5 [9334580.001]
  • [Cites] N Engl J Med. 2001 Dec 6;345(23 ):1711-2 [11759660.001]
  • [Cites] J Clin Oncol. 2000 Dec 15;18(24):4009-15 [11118461.001]
  • [Cites] Cancer Res. 1995 Sep 15;55(18):4182-7 [7664295.001]
  • [Cites] Br J Cancer. 1998 Apr;77(8):1311-7 [9579838.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3127-32 [12915604.001]
  • (PMID = 15610695.001).
  • [ISSN] 1527-2737
  • [Journal-full-title] Current urology reports
  • [ISO-abbreviation] Curr Urol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 0 / Interleukins; 9008-11-1 / Interferons
  • [Number-of-references] 51
  •  go-up   go-down


15. Obana T, Tanio Y, Takenaka M, Watanabe D, Yanagita M, Nakajima S, Okuda K, Tsubakihara Y, Fushimi H: [Chemotherapy for small-cell lung cancer (SCLC) patients with renal failure]. Gan To Kagaku Ryoho; 2002 Mar;29(3):435-8
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemotherapy for small-cell lung cancer (SCLC) patients with renal failure].
  • We administered chemotherapy in three cases of small-cell lung cancer (SCLC) with renal failure under different situations.
  • Hemodialysis (HD) was used in 2 out of the 3 cases.
  • Case 1 was complicated by acute renal failure from extensive bilateral tumor invasion.
  • After chemotherapy (CBDCA + ETP) under HD, renal metastases regressed and renal function improved, although the final response was PD.
  • After 2 cycles of chemotherapy (CBDCA + ETP) under HD, the patient attained a PR.
  • Case 3 is an example of paraneoplastic nephrotic syndrome with renal failure.
  • Chemotherapy including CBDCA or CDDP was performed and the QOL of the patient improved.
  • In conclusion, individualized therapy is necessary to increase survival time of SCLC patients with renal failure.
  • Although chemotherapy is useful, further study is needed for the selection of suitable chemotherapeutic regimens, optimal dosage of each drug and the timing of HD.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Lung Neoplasms / drug therapy. Paraneoplastic Polyneuropathy / drug therapy. Renal Insufficiency / complications
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Carboplatin / pharmacokinetics. Drug Administration Schedule. Etoposide / administration & dosage. Etoposide / pharmacokinetics. Humans. Kidney Neoplasms / complications. Kidney Neoplasms / secondary. Male. Middle Aged. Renal Dialysis

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11915735.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


16. Botteman MF, Kaura S: Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases from renal cell carcinoma: Comparison between France, Germany, and the United Kingdom. J Clin Oncol; 2009 May 20;27(15_suppl):5106

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases from renal cell carcinoma: Comparison between France, Germany, and the United Kingdom.
  • : 5106 Background: Zoledronic acid (ZOL) significantly reduces the risk of new skeletal-related events (SREs) in patients (pts) with bone metastases from RCC.
  • METHODS: This analysis was based on a retrospective analysis of RCC pts with bone metastases who were enrolled in a 9-mo trial of ZOL or placebo (PBO) plus concomitant antineoplastic therapy.
  • A model was developed to simulate costs and quality-adjusted life-years (QALYs) experienced by study pts.
  • The model included data and assumptions regarding SRE incidence, mortality, drug and administration costs, SRE costs, reduced quality of life (QOL) because of SREs and bone pain, and therapy duration.
  • SRE costs were estimated using diagnosis-related group tariff information and published literature.
  • Consistent with similar economic analyses, it was assumed that QOL decreased 20% to 80% (depending on SRE type) for 1 mo after each SRE experienced.
  • After including drug therapy costs, ZOL saved 1,358, 1,223, and 719 per pt in France, Germany, and the UK, respectively.
  • CONCLUSIONS: Treatment with ZOL reduces SREs, improves QOL, and lowers health-related costs compared with PBO in French, German, and UK pts with bone metastases from RCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964368.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Mancuso A, Sternberg CN: New treatments for metastatic kidney cancer. Can J Urol; 2005 Feb;12 Suppl 1:66-70; discussion 105
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New treatments for metastatic kidney cancer.
  • Renal cell carcinoma accounts for approximately 3% of adult malignancies and 90%-95% of neoplasms arising from the kidney.
  • It is characterized by a lack of early warning signs, diverse clinical manifestations, resistance to radiation and chemotherapy, and infrequent but reproducible responses to immunotherapy with agents such as interferon alpha (IFNa) and interleukin 2 (IL-2).
  • International studies have shown objective response rates of < 15% in patients with advanced and metastatic disease, with 5-year disease-specific survival ranging between 0-20%.
  • Considering these poor outcomes, renal cancers' very vascular nature and overexpression of receptors for vascular endothelial growth factor (VEGF), various biologic and angio-suppressive therapies are being evaluated in clinical trials.
  • Promising results in terms of overall response rate and median time to progression have been reported especially as second-line therapy following cytokine failure, a setting where no effective systemic therapy has been recognized (SU011248, Bay 43-9006, Bevacizumab and Erlotinib).
  • While confirmatory studies are ongoing, other novel treatments in first line trials (CCI-779, Infliximab, PTK-787, and Thalidomide) have drawn international attention.
  • This review, analyzing basic translational research principles, will summarize the available data on the use of these new therapeutic approaches in RCC.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Carcinoma, Renal Cell / secondary. Carcinoma, Renal Cell / therapy. Immunotherapy / methods. Kidney Neoplasms / pathology. Kidney Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Prognosis. Risk Assessment. Sensitivity and Specificity. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15780170.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors
  • [Number-of-references] 32
  •  go-up   go-down


18. Vogelzang NJ, Aklilu M, Stadler WM, Dumas MC, Mikulski SM: A phase II trial of weekly intravenous ranpirnase (Onconase), a novel ribonuclease in patients with metastatic kidney cancer. Invest New Drugs; 2001;19(3):255-60
SciCrunch. DrugBank: Data: Chemical .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of weekly intravenous ranpirnase (Onconase), a novel ribonuclease in patients with metastatic kidney cancer.
  • Ranpirnase (Onconase) is the first ribonuclease to enter cancer clinical trials.
  • This phase II trial tested ranpirnase (480 microg/m2/w) in 14 patients with refractory advanced renal cell cancer.
  • All patients had prior immunotherapy and three had prior chemotherapy.
  • At this dose and schedule ranpirnase has minimal activity in metastatic renal cell cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Renal Cell / drug therapy. Kidney Neoplasms / drug therapy. Ribonucleases / therapeutic use
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Mar 15;88(6):1317-24 [10717612.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):497-501 [7844611.001]
  • [Cites] Lancet. 1998 Nov 21;352(9141):1691-6 [9853456.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(12):2419-26 [10856102.001]
  • [Cites] Proteins. 1992 Nov;14 (3):392-400 [1438177.001]
  • [Cites] Cancer J Sci Am. 1997 Dec;3 Suppl 1:S73-8 [9457399.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1820-5 [9586896.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10):2766-72 [10537340.001]
  • [Cites] J Urol. 1999 Jul;162(1):155-6 [10379761.001]
  • [Cites] J Clin Oncol. 1995 Aug;13(8):1950-7 [7636535.001]
  • [Cites] J Clin Oncol. 1999 Aug;17 (8):2541-5 [10561320.001]
  • [Cites] Clin Cancer Res. 1998 Apr;4(4):929-34 [9563886.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2530-40 [10561319.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 17;82(2):151-3 [2294226.001]
  • [Cites] Int J Oncol. 1995 Apr;6(4):889-97 [21556617.001]
  • [Cites] J Mol Biol. 1994 Mar 4;236(4):1141-53 [8120892.001]
  • [Cites] J Clin Oncol. 1993 Apr;11(4):661-70 [8478661.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1983-94 [10766189.001]
  • [Cites] Cancer. 1997 Oct 1;80(7):1198-220 [9317170.001]
  • [Cites] Lancet. 1999 Jan 2;353(9146):14-7 [10023944.001]
  • [Cites] N Engl J Med. 1998 Apr 30;338(18):1272-8 [9562581.001]
  • [Cites] J Clin Oncol. 1999 Sep;17 (9):2859-67 [10561363.001]
  • [Cites] Int J Oncol. 1993 Jul;3(1):57-64 [21573326.001]
  • [Cites] Cell Tissue Kinet. 1988 May;21(3):169-82 [3224365.001]
  • [Cites] J Natl Cancer Inst. 1996 Jun 5;88(11):747-53 [8637029.001]
  • [Cites] Cell Tissue Kinet. 1990 May;23 (3):237-46 [2357721.001]
  • [Cites] J Biol Chem. 1991 Jan 5;266(1):245-51 [1985896.001]
  • [Cites] J Clin Oncol. 1993 Sep;11(9):1809-16 [8355047.001]
  • (PMID = 11561684.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 3.1.- / Ribonucleases; ZE15FIT23E / ranpirnase
  •  go-up   go-down


19. Negrier S, Douillard JY, Gomez F, Lasset C, Chevreau C, Escudier B, French Immunotherapy Group: [Interleukin-2 and interferon in metastatic kidney cancer. Experience of the French Immunotherapy Group]. Prog Urol; 2002 Apr;12(2):213-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Interleukin-2 and interferon in metastatic kidney cancer. Experience of the French Immunotherapy Group].
  • [Transliterated title] Interleukine-2 et interféron dans le cancer du rein métastatique L'expérience du Groupe Français d'Immunothérapie.
  • The authors report the experience of the investigators of the Groupe Français d'Immunotherapie in the treatment of metastatic renal cancer by cytokines based on several clinical trials conducted successively between 1991 and 1998.
  • This group initially conducted a large-scale randomized trial reported in the New England Journal of Medicine in 1999, comparing three treatment regimens: intravenous interleukin-2, interferon alone and a combination of these two treatment modalities.
  • A subgroup of patients was identified with a probability of progression during treatment greater than 70% and a median survival of 6 months.
  • These patients concomitantly presented initial metastases during the year following the diagnosis of renal cancer, involving several organs including the liver.
  • [MeSH-major] Cytokines / therapeutic use. Interferons / therapeutic use. Interleukin-2 / therapeutic use. Kidney Neoplasms / drug therapy
  • [MeSH-minor] Drug Therapy, Combination. Humans. Neoplasm Metastasis. Randomized Controlled Trials as Topic

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12108334.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-2; 9008-11-1 / Interferons
  • [Number-of-references] 15
  •  go-up   go-down


20. Jingu K, Sasagawa K, Kagaya A, Ochiai T: [A case of stage IV gastric cancer previously treated with TS-1 completely responding to second-line chemotherapy with weekly paclitaxel therapy]. Gan To Kagaku Ryoho; 2005 Dec;32(13):2117-20
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of stage IV gastric cancer previously treated with TS-1 completely responding to second-line chemotherapy with weekly paclitaxel therapy].
  • We report herein a case with stage IV gastric cancer previously treated with TS-1 completely responding to second-line chemotherapy with weekly paclitaxel therapy.
  • A 65-year-old female was diagnosed as having type 3 gastric cancer with para-aortic lymph node metastases.
  • Histopathological examination revealed that the tumor was poorly-differentiated adenocarcinoma with para-aortic lymph nodes metastases and completely resected.
  • After the operation,she was treated by adjuvant chemotherapy with TS-1.
  • In March of 2004, she suffered from hematuria, and a CT scan revealed para-aortic lymph nodes metastases and left kidney metastasis.
  • Then, she was treated by a weekly infusion of paclitaxel as second-line chemotherapy.
  • After 3 courses, the tumor disappeared and efficacy was judged as CR.
  • Therefore, weekly paclitaxel therapy was considered to be one of the promising second-line chemotherapies for advanced or recurrent gastric cancer previously treated by TS-1.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / administration & dosage. Paclitaxel / administration & dosage. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Chemotherapy, Adjuvant. Drug Administration Schedule. Drug Combinations. Female. Gastrectomy. Humans. Kidney Neoplasms / drug therapy. Kidney Neoplasms / secondary. Lymph Nodes / pathology. Lymphatic Metastasis. Neoplasm Staging. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Remission Induction. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16352940.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


21. Cornu JN, Rouprêt M, Bensalah K, Oudard S, Patard JJ: [Antiangiogenics: new therapeutic standards in metastatic kidney cancer]. Prog Urol; 2008 Jul;18 Suppl 4:S69-76
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Antiangiogenics: new therapeutic standards in metastatic kidney cancer].
  • [Transliterated title] Les anti-angiogéniques: de nouveaux standards thérapeutiques dans le cancer du rein métastatique.
  • Since 2004, the treatment of metastatic renal cell carcinoma is in deep mutation.
  • From 2004, studies of new antiangiogenic molecules, acting on the pVHL-HIF way, VEGF, PDGF or tyrosine-kinase receptors have modified the management of metastatic patients.
  • Antiangiogenic agents improve progression-free survival as shown with sunitinib, in first line treatment, or sorafenib, as second line treatment.
  • The m-TOR inhibitors (Temsirolimus), can be used with a benefit on overall survival in case of poor prognosis renal cell carcinoma or non clear cell carcinoma.
  • Nevertheless, the place of these molecules have to be defined in the sequence of the treatment.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Kidney Neoplasms / drug therapy. Kidney Neoplasms / pathology
  • [MeSH-minor] Benzenesulfonates / therapeutic use. Humans. Indoles / therapeutic use. Neoplasm Metastasis / drug therapy. Niacinamide / analogs & derivatives. Phenylurea Compounds. Pyridines / therapeutic use. Pyrroles / therapeutic use

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18706374.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Benzenesulfonates; 0 / Indoles; 0 / Phenylurea Compounds; 0 / Pyridines; 0 / Pyrroles; 0 / sunitinib; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


22. Herrmann E, Gerss J, Bierer S, Köpke T, Bolenz C, Hertle L, Wülfing C: Pre-treatment global quality of health predicts progression free survival in metastatic kidney cancer patients treated with sorafenib or sunitinib. J Cancer Res Clin Oncol; 2009 Jan;135(1):61-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pre-treatment global quality of health predicts progression free survival in metastatic kidney cancer patients treated with sorafenib or sunitinib.
  • PURPOSE: Our goal was to prospectively evaluate self-reported quality-of-life (QoL) during second-line therapy in 51 consecutive patients with cytokine-refractory kidney cancer treated with sorafenib or sunitinib.
  • RESULTS: Global QoL deteriorated significantly during the first 4 weeks of treatment (P < 0.0001).
  • After 16 weeks, fatigue (P < 0.0001), pain (P = 0.015), appetite loss (P = 0.002) and diarrhoea (P = 0.038) were still influenced by the therapy, while all functional scales recovered.
  • CONCLUSIONS: Second-line therapy with sorafenib or sunitinib does not adversely affect patients global QoL after 16 weeks of treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Renal Cell / mortality. Indoles / therapeutic use. Kidney Neoplasms / mortality. Pyridines / therapeutic use. Pyrroles / therapeutic use. Quality of Life
  • [MeSH-minor] Adolescent. Adult. Disease-Free Survival. Female. Health Surveys. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / drug therapy. Neoplasm Staging. Niacinamide / analogs & derivatives. Palliative Care. Phenylurea Compounds. Prognosis. Prospective Studies. Salvage Therapy. Surveys and Questionnaires. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2001 Dec 6;345(23 ):1655-9 [11759643.001]
  • [Cites] Eur J Cancer Care (Engl). 2004 May;13(2):135-44 [15115469.001]
  • [Cites] J Clin Oncol. 2004 Feb 1;22(3):454-63 [14752067.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3612-20 [10550161.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] Lancet. 2001 Sep 22;358(9286):966-70 [11583750.001]
  • [Cites] J Natl Cancer Inst. 1993 Mar 3;85(5):365-76 [8433390.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2516-24 [16757724.001]
  • [Cites] Eur Urol. 2007 Jun;51(6):1502-10 [17408850.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):139-44 [9440735.001]
  • [Cites] J Clin Oncol. 2008 Jan 1;26(1):127-31 [18165647.001]
  • [Cites] Semin Radiat Oncol. 2003 Jul;13(3):176-81 [12903007.001]
  • [Cites] Br J Cancer. 2003 Jul 7;89(1):50-4 [12838299.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):16-24 [16330672.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2376-81 [11981011.001]
  • [Cites] Am J Clin Oncol. 2007 Jun;30(3):220-7 [17551296.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • (PMID = 18592270.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Indoles; 0 / Phenylurea Compounds; 0 / Pyridines; 0 / Pyrroles; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib; V99T50803M / sunitinib
  •  go-up   go-down


23. Vozianov AF, Zak KP, Zubko VI, Romanenko AM, Klimenko IA, Babich VM, Kushneruk IuI, Shcherbak AIu, Bazalitskaia SV, Gruzov MA: [Clinical and immunological studies of the therapeutical effect of cytokines combined with 5-fluorouracil in metastatic kidney cancer]. Lik Sprava; 2002;(7):41-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical and immunological studies of the therapeutical effect of cytokines combined with 5-fluorouracil in metastatic kidney cancer].
  • The authors present the results of a six-year clinicoimmunological study of a therapeutic effect of cytkins combined with 5-fluoruracyl in metastatic renal-cell carcinoma.
  • Two therapeutic regiments have been used: rhIFN-a + 5-FU and rhIL-2 + RHifn-A + 5-FU.
  • In cytokin-sensitive patients, both therapy protocols vrs conventional therapeutic alternatives (cytostatics, hormones, irradiation) have been shown to increase the frequency of achievement of remission by objective scoring and life span of the patients.
  • There was an improvement in patients on having received the complex with IL-2 but a higher therapeutic effect appeared to be accompanied by substantial side effects.
  • Recommendatory measures well-targeted to those patients with metastatic renal-cell carcinoma who are to be placed on cytokinotherapy are presented together with immunological indices to monitor the treatments administered and prognosis.

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12587303.001).
  • [ISSN] 1019-5297
  • [Journal-full-title] Likars'ka sprava
  • [ISO-abbreviation] Lik. Sprava
  • [Language] RUS
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Interleukin-2; 0 / Recombinant Proteins; 76543-88-9 / interferon alfa-2a; 99210-65-8 / interferon alfa-2b; U3P01618RT / Fluorouracil
  •  go-up   go-down


24. Ferrière JM, Wallerand H, Bernhard JC, Cornu JN, Rouprêt M, Ravaud A: [The advantages of antiangiogenics in neoadjuvant and adjuvant locally advanced and metastatic kidney cancer: two case studies]. Prog Urol; 2008 Jul;18 Suppl 4:S88-91
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The advantages of antiangiogenics in neoadjuvant and adjuvant locally advanced and metastatic kidney cancer: two case studies].
  • [Transliterated title] Intérêt des anti-angiogéniques dans le cancer du rein localement avancé et métastatique en situation néo-adjuvante: à propos de 2 cas.
  • New antiangiogenic molecules have proven an advantage in term of survival in metastatic renal cell carcinoma.
  • We describe herein two clinical cases showing the efficacy of antiangiogenic agent in locally advanced or metastatic renal cell carcinoma.
  • In this cases the surgical management has been altered in front of an important tumor necrosis provided by this treatment.
  • The role of antiangiogenic agents as adjuvant or neo adjuvant therapy has not yet been defined precisely.
  • However, these new molecules open new perspectives in the therapeutic field of metastatic renal cell carcinoma notably in case of bulky tumors which appeared difficult to remove surgically at first look or in case of early recurrence after radical nephrectomy.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Carcinoma, Renal Cell / drug therapy. Kidney Neoplasms / drug therapy
  • [MeSH-minor] Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18706377.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors
  •  go-up   go-down


25. Dogan M, Ozal G, Ekinci C, Utkan G, Urun Y, Yalcin B, Icli F: Two cases with atypical metastasis in colorectal cancer: splenic and renal metastasis. Exp Oncol; 2010 Dec;32(4):277-9
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two cases with atypical metastasis in colorectal cancer: splenic and renal metastasis.
  • Atypical metastasis, such as splenic and renal metastasis is rare in colorectal cancer.
  • There have been case reports of colorectal cancer patients with isolated splenic metastasis, even after years of surgery in the literature.
  • AIM: To report two colorectal cancer cases with atypical metastasis.
  • RESULTS: The first patient was a 58-year old man who had isolated splenic metastasis after 20 months of surgery.
  • The other one was a 51-year old male patient with both lung and renal metastasis at rectal cancer diagnosis.
  • Splenic and renal metastases have been histopathologically documented in both of them.
  • The first patient was given chemotherapy after splenectomy.
  • The other one had also multiple lung metastases besides renal metastasis.
  • He received palliative chemotherapy.
  • [MeSH-major] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology. Kidney Neoplasms / secondary. Splenic Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Digestive System Surgical Procedures. Humans. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Male. Middle Aged. Palliative Care


26. Siebels M, Staehler M, Hegele A, Varga Z, Oberneder R, Doehn C, Heinzer H, Deutsche Gesellschaft für Immun- und Targeted Therapie e.V. (DGFIT): [Impact of immunotherapy in metastatic kidney cancer in Germany after introduction of new target therapy--results of a telephone survey of the German Society of Immuno- and Targeted Therapy (DGFIT)]. Aktuelle Urol; 2010 Mar;41(2):122-30
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Impact of immunotherapy in metastatic kidney cancer in Germany after introduction of new target therapy--results of a telephone survey of the German Society of Immuno- and Targeted Therapy (DGFIT)].
  • [Transliterated title] Welche Bedeutung hat die Immuntherapie beim metastasierten Nierenzell-karzinom nach Einführung der neuen Target-Substanzen in Deutschland--Ergebnisse einer repräsentativen Umfrage der DGFIT.
  • INTRODUCTION: Until recently, the standard therapy for metastatic renal cell carcinoma (mRCC) in Germany consisted of interleukin-2 (IL-2), interferon-alfa (IFN) as single agents or in combination, with or without chemotherapy.
  • Since 2005, new drugs (target drugs) in the therapy for mRCC are available.
  • The aim of this study was to analyse the current therapy standard in Germany.
  • Screening criteria were 1) responsibility for therapy in mRCC;.
  • 2) therapy of at least 10 patients with mRCC per year.
  • 98% of patients with mRCC were treated: A: the most frequent therapy was sunitinib (43%, 42%, 33% as first-, second-, third-line), B: the most frequent therapy was sunitinib (45% as first-line, 37% as second-line), the most frequent third-line therapy was sorafenib (35%); C: the most frequent therapy were sorafenib and sunitinib (first-line 26% vs. 27%, second-line 46% vs. 42%), in third-line therapy additionally temsirolimus 24%; D: primary sorafenib and sunitinib (first-line 33% vs. 40%, second-line 46% vs. 42%), in third-line therapy additionally temsirolimus 23%.
  • Immunotherapy (IL-2, IFN with or without chemotherapy) in mRCC plays in Germany for the second- and third-line therapy in A-D no major role (less than 10%).
  • Otherwise, for first-line therapy immunotherapy has some relevance: A: 25%, B: 37%, C: 33%, D: 16%.
  • The most important criteria for therapy decision making in A-D were: efficacy, toxicity, drug approval status.
  • Sunitinib (in first-line) and sorafenib (in second-line) are currently the most frequent prescribed drugs in mRCC.
  • Temsirolimus is used mostly for third-line therapy (followed by sunitinib/sorafenib).
  • Treatment of mRCC in Germany is increasingly being performed by oncologists.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Renal Cell / drug therapy. Carcinoma, Renal Cell / secondary. Drug Delivery Systems / methods. Immunotherapy / methods. Indoles / therapeutic use. Kidney Neoplasms / drug therapy. Pyridines / therapeutic use. Pyrroles / therapeutic use. Sirolimus / analogs & derivatives
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Attitude of Health Personnel. Cooperative Behavior. Data Collection. Drug Utilization / statistics & numerical data. Germany. Humans. Interdisciplinary Communication. Interferon-alpha / therapeutic use. Interleukin-2 / therapeutic use. Medical Oncology. Niacinamide / analogs & derivatives. Patient Care Team. Phenylurea Compounds. Urology

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag Stuttgart New York.
  • (PMID = 19937556.001).
  • [ISSN] 1438-8820
  • [Journal-full-title] Aktuelle Urologie
  • [ISO-abbreviation] Aktuelle Urol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Indoles; 0 / Interferon-alpha; 0 / Interleukin-2; 0 / Phenylurea Compounds; 0 / Pyridines; 0 / Pyrroles; 0 / sunitinib; 25X51I8RD4 / Niacinamide; 624KN6GM2T / temsirolimus; 9ZOQ3TZI87 / sorafenib; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


27. Martino L, Martino F, Coluccio A, Mangiarini MG, Chioda C: Renal metastasis from pancreatic adenocarcinoma. Arch Ital Urol Androl; 2004 Mar;76(1):37-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal metastasis from pancreatic adenocarcinoma.
  • The Authors describe a case of a man (68 years) affected by renal metastasis from pancreatic adenocarcinoma.
  • Additional metastases had been detected in the liver, in the spleen and in the small intestine.
  • After surgery the patient refused adjuvant chemotherapy.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15185821.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 14
  •  go-up   go-down


28. Doehn C, Kausch I, Melz S, Behm A, Jocham D: Cytokine and vaccine therapy of kidney cancer. Expert Rev Anticancer Ther; 2004 Dec;4(6):1097-111
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokine and vaccine therapy of kidney cancer.
  • In this paper, results from current randomized and other relevant studies on cytokine and vaccine therapy of kidney cancer in the adjuvant setting and in metastatic disease are reviewed.
  • Improvement of medical therapy of kidney cancer is required since the relative 5-year survival of kidney cancer is only 62%.
  • Recently, an autologous kidney cancer cell vaccine has been shown to reduce the risk of tumor progression following radical nephrectomy for organ-confined or locally advanced kidney cancer in a randomized Phase III study.
  • Presently, this is the only promising approach for the adjuvant treatment of kidney cancer following nephrectomy.
  • In metastatic kidney cancer patients with the tumor-bearing kidney in situ, a combination of radical nephrectomy plus IFN-alpha is more effective than IFN-alpha alone.
  • In metastatic kidney cancer without the option of operative removal of the primary tumor and/or metastases, cytokines such as IFN-alpha, IL-2 and IL-12 and their combinations result in response rates of 10-30%, but the 5-year overall survival is less than 10%.
  • Vaccine therapy of metastatic kidney cancer has been investigated only in Phase I and II studies with limited clinical benefit.
  • Based on the current literature there is a clear need for new approaches in metastatic kidney cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cancer Vaccines / therapeutic use. Interferon-alpha / therapeutic use. Interleukin-12 / therapeutic use. Interleukin-2 / therapeutic use. Kidney Neoplasms / drug therapy. Kidney Neoplasms / immunology
  • [MeSH-minor] Chemotherapy, Adjuvant. Disease-Free Survival. Humans. Neoplasm Metastasis. Prognosis. Randomized Controlled Trials as Topic

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15606336.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cancer Vaccines; 0 / Interferon-alpha; 0 / Interleukin-2; 187348-17-0 / Interleukin-12
  • [Number-of-references] 64
  •  go-up   go-down


29. Cooney MM, Remick SC, Vogelzang NJ: Promising systemic therapy for renal cell carcinoma. Curr Treat Options Oncol; 2005 Sep;6(5):357-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promising systemic therapy for renal cell carcinoma.
  • In the United States, advanced kidney cancer accounts for over 12,000 deaths each year.
  • Interferon is a less active agent than IL-2 but it has still been shown to be superior to therapy with either megesterol or vinblastine.
  • Interferon typically results in very few long-term responses and is given to most patients with metastatic kidney cancer.
  • Median survival after interferon therapy is dependent on risk group but is typically 12 to 15 months.
  • Thus, new therapies are urgently needed in this refractory disease.
  • Novel compounds currently being tested in clinical trials are showing promise in advanced kidney cancer.
  • The molecular targets of these drugs include interfering with the vascular endothelial growth factor receptors or the raf kinase pathway, angiogenesis inhibition, and antimicrotubule agents.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Renal Cell / drug therapy. Kidney Neoplasms / drug therapy
  • [MeSH-minor] Animals. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Benzenesulfonates / administration & dosage. Bevacizumab. Drug Administration Schedule. Epothilones / administration & dosage. Erlotinib Hydrochloride. Humans. Indoles / administration & dosage. Niacinamide / analogs & derivatives. Phenylurea Compounds. Pyridines / administration & dosage. Pyrroles / administration & dosage. Quinazolines / administration & dosage. Thalidomide / administration & dosage. Thalidomide / analogs & derivatives

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Ixabepilone .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1999 May 20;399(6733):271-5 [10353251.001]
  • [Cites] N Engl J Med. 2001 Dec 6;345(23 ):1655-9 [11759643.001]
  • [Cites] Cell Signal. 2003 May;15(5):463-9 [12639709.001]
  • [Cites] J Biol Chem. 2000 Aug 18;275(33):25733-41 [10823831.001]
  • [Cites] Epidemiology. 1999 Mar;10(2):188-91 [10069258.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Br J Cancer. 2002 Nov 4;87(10):1166-72 [12402158.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):832-41 [15681528.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1289-98 [14977827.001]
  • [Cites] Oncogene. 1999 Feb 25;18(8):1529-35 [10102622.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2530-40 [10561319.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):302-6 [11773183.001]
  • [Cites] Lancet. 1999 Jan 2;353(9146):14-7 [10023944.001]
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] N Engl J Med. 2003 Jul 31;349(5):427-34 [12890841.001]
  • [Cites] J Clin Oncol. 1999 Sep;17 (9):2859-67 [10561363.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10430-5 [10973499.001]
  • [Cites] Chin Med J (Engl). 2001 Feb;114(2):139-42 [11780193.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1429-37 [11350914.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3063-7 [12384400.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3770-6 [14551295.001]
  • [Cites] Curr Pharm Des. 2002;8(25):2249-53 [12369852.001]
  • [Cites] Oncology (Williston Park). 2003 Nov;17(11 Suppl 12):11-6 [14682118.001]
  • [Cites] J Urol. 1999 Oct;162(4):1246-58 [10492174.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3127-32 [12915604.001]
  • (PMID = 16107239.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Epothilones; 0 / Indoles; 0 / Phenylurea Compounds; 0 / Pyridines; 0 / Pyrroles; 0 / Quinazolines; 25X51I8RD4 / Niacinamide; 2S9ZZM9Q9V / Bevacizumab; 4Z8R6ORS6L / Thalidomide; 9ZOQ3TZI87 / sorafenib; DA87705X9K / Erlotinib Hydrochloride; F0P408N6V4 / lenalidomide; K27005NP0A / ixabepilone; V99T50803M / sunitinib
  • [Number-of-references] 44
  •  go-up   go-down


30. Temsirolimus and mantle cell lymphoma. Highly toxic, limited efficacy. Prescrire Int; 2010 Dec;19(111):276-8
Hazardous Substances Data Bank. SIROLIMUS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mantle cell lymphoma is a highly malignant non-Hodgkin's lymphoma.
  • There is no consensus on chemotherapy regimens for patients who do not qualify for haematopoietic stem cell transplantation.
  • Temsirolimus, a metabolic precursor of sirolimus, already marketed in the European Union for metastatic kidney cancer, recently received an extension of indications to include relapsed or refractory mantle cell lymphoma.
  • In this setting, one trial involving 162 patients in whom 2 or 3 chemotherapy regimens had failed compared two doses of temsirolimus (175 mg per week for 3 weeks, followed by 75 mg or 25 mg per week) versus a control group receiving various other treatments.
  • The median overall survival time was about 11 months, regardless of the treatment.The median survival time before radiological or clinical progression was slightly longer with the higher dose of temsirolimus than in the control group (4.8 versus 1.9 months).
  • In practice, temsirolimus shows only limited efficacy but is highly toxic in patients with relapsed or refractory mantle cell lymphoma after several prior chemotherapy regimens.
  • It is better to avoid using this drug.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Lymphoma, Mantle-Cell / drug therapy. Sirolimus / analogs & derivatives
  • [MeSH-minor] Drug Packaging. Humans

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21355378.001).
  • [ISSN] 1167-7422
  • [Journal-full-title] Prescrire international
  • [ISO-abbreviation] Prescrire Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 624KN6GM2T / temsirolimus; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


31. Hoshi K, Kanbara T, Kawasaki Y, Ikeda Y, Namima T, Ohnuma T: [Pulmonary and lymph node metastases of renal cell carcinoma which completely responded to oral administration of UFT--a case report]. Gan To Kagaku Ryoho; 2007 Aug;34(8):1315-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary and lymph node metastases of renal cell carcinoma which completely responded to oral administration of UFT--a case report].
  • In April 2003, a 59-year-old woman suffering from renal cell carcinoma (RCC) underwent radical nephrectomy (Stage I).
  • Histologically, resected specimens were diagnosed as metastases from RCC.
  • However, 2 months later,lung and abdominal lymph node metastases were detected by CT.
  • Chemotherapy with interferon-alpha (IFN-alpha) 6,000,000 units every day was performed, but was discontinued after 3 months due to fatigue and depression.
  • Because the tumor marker (IAP) level and the size of the metastatic tumors increased, second-line chemotherapy with oral administration of tegafur/uracil (UFT-E 600 mg/day) was started.
  • Six months after UFT administration, there was a significant decrease of tumor markers and the metastatic tumors were disappeared, therefore we were judged as complete response (CR).
  • Some cases may be effectively treated by UFT after treatment failure of IFN-alpha therapy.
  • This UFT therapy is simple and possible to continue safely on an outpatient chemotherapy while maintaining quality of life.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Renal Cell / drug therapy. Kidney Neoplasms / drug therapy. Lung Neoplasms / secondary. Lymph Nodes / pathology. Tegafur / administration & dosage. Uracil / administration & dosage
  • [MeSH-minor] Administration, Oral. Chemotherapy, Adjuvant. Drug Administration Schedule. Drug Combinations. Female. Humans. Lymphatic Metastasis. Middle Aged. Nephrectomy. Pneumonectomy. Quality of Life. Remission Induction

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17687222.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Combinations; 0 / UFT(R) drug; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil
  •  go-up   go-down


32. Sibaud V, Delord JP, Chevreau C: Sorafenib-induced hand-foot skin reaction: a Koebner phenomenon? Target Oncol; 2009 Dec;4(4):307-10
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sorafenib is a tyrosine kinase inhibitor prescribed primarily for the management of metastatic kidney cancer.
  • [MeSH-minor] Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Carcinoma, Renal Cell / drug therapy. Humans. Kidney Neoplasms / drug therapy. Niacinamide / analogs & derivatives. Phenylurea Compounds. Prognosis. Skin Diseases / chemically induced. Skin Tests

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2007 Jan 20;25(3):341-3 [17235051.001]
  • [Cites] Ann Oncol. 2008 Nov;19(11):1955-61 [18550575.001]
  • [Cites] Br J Dermatol. 2008 Mar;158(3):592-6 [18070211.001]
  • [Cites] Arch Dermatol. 2008 Jun;144(6):820-2 [18559790.001]
  • [Cites] Br J Dermatol. 2009 Nov;161(5):1045-51 [19558553.001]
  • [Cites] Ann Dermatol Venereol. 2008 Jan;Spec No 1:16-24 [18342113.001]
  • [Cites] Lancet Oncol. 2005 Jul;6(7):491-500 [15992698.001]
  • [Cites] Eur J Cancer. 2008 Apr;44(6):781-90 [18331788.001]
  • [Cites] J Clin Oncol. 2008 Jun 1;26(16):2790-2 [18509193.001]
  • [Cites] Clin Cancer Res. 2009 Feb 15;15(4):1411-6 [19228742.001]
  • [Cites] Acta Oncol. 2008;47(2):176-86 [18210295.001]
  • [Cites] Arch Dermatol. 2008 Jul;144(7):886-92 [18645140.001]
  • [Cites] Invest New Drugs. 2009 Aug;27(4):389-90 [18998055.001]
  • [Cites] J Am Acad Dermatol. 2009 Feb;60(2):299-305 [19028406.001]
  • [Cites] J Am Acad Dermatol. 1999 Mar;40(3):367-98; quiz 399-400 [10071309.001]
  • [Cites] Oncologist. 2008 Sep;13(9):1001-11 [18779536.001]
  • (PMID = 19894099.001).
  • [ISSN] 1776-260X
  • [Journal-full-title] Targeted oncology
  • [ISO-abbreviation] Target Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


33. Fokt RM, Templeton A, Gillessen S, Ohlschlegel C, Schmid HP: Prostatic metastasis of renal cell carcinoma successfully treated with sunitinib. Urol Int; 2009;83(1):122-4
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostatic metastasis of renal cell carcinoma successfully treated with sunitinib.
  • Metastases of renal cell carcinoma to the prostate gland are very rare.
  • We present a case of a metastasis of renal cell carcinoma in the prostate which occurred 10 years after nephrectomy.
  • Treatment with sunitinib was initiated and a notable response achieved.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Renal Cell / drug therapy. Carcinoma, Renal Cell / secondary. Indoles / therapeutic use. Kidney Neoplasms / pathology. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / secondary. Pyrroles / therapeutic use

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19641373.001).
  • [ISSN] 1423-0399
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Indoles; 0 / Pyrroles; 0 / sunitinib
  • [Number-of-references] 14
  •  go-up   go-down


34. Dasanu CA, Alexandrescu DT, Dutcher J: Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma. South Med J; 2007 Mar;100(3):328-30
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma.
  • This report describes a patient with metastatic kidney cancer who developed a deep yellow skin discoloration while on therapy with the oral multitargeted tyrosine kinase inhibitor (TKI), sorafenib.
  • A thorough clinicolaboratory investigation did not reveal any evidence of jaundice, B12 deficiency, anemia, carotenemia, hypothyroidism, or any other disorder of endocrine or metabolic etiology.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Benzenesulfonates / adverse effects. Carcinoma, Renal Cell / secondary. Pigmentation Disorders / chemically induced. Protein Kinase Inhibitors / adverse effects. Pyridines / adverse effects. raf Kinases / antagonists & inhibitors
  • [MeSH-minor] Acrodermatitis / chemically induced. Erythema / chemically induced. Humans. Kidney Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Male. Middle Aged. Niacinamide / analogs & derivatives. Phenylurea Compounds. Spinal Neoplasms / secondary

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Skin Pigmentation Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] South Med J. 2007 May;100(5):485
  • (PMID = 17396743.001).
  • [ISSN] 0038-4348
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib; EC 2.7.11.1 / raf Kinases
  •  go-up   go-down


35. Gross-Goupil M, Escudier B: [Targeted therapies: sequential and combined treatments]. Bull Cancer; 2010;97:65-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Targeted therapies: sequential and combined treatments].
  • The treatment of metastatic kidney cancer has dramatically changed in the last three years, with demonstration of efficacy of sunitinib, sorafenib, temsirolimus, bevacizumab combined with interferon and more recently everolimus.
  • Particularly, the best order of administration of these targeted therapies should be considered, since sequential schedule becomes usual with the availability of these new agents.
  • At the same time, the tolerability and efficacy of the combination of the targeted therapies are under investigation in clinical trials.
  • Furthermore, other studies are ongoing to answer other important questions, to optimize the treatment of this disease, such as the role of nephrectomy in case of synchronous metastatic disease, or the efficacy of the targeted therapies in different histological subtype than clear cell carcinoma, or in neoadjuvant and adjuvant settings.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Kidney Neoplasms / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Benzenesulfonates / therapeutic use. Bevacizumab. Combined Modality Therapy. Cytokines / therapeutic use. Humans. Indoles / therapeutic use. Interferon-alpha / therapeutic use. Intracellular Signaling Peptides and Proteins / antagonists & inhibitors. Intracellular Signaling Peptides and Proteins / metabolism. Nephrectomy. Niacinamide / analogs & derivatives. Phenylurea Compounds. Protein Kinase Inhibitors / therapeutic use. Protein-Serine-Threonine Kinases / antagonists & inhibitors. Protein-Serine-Threonine Kinases / metabolism. Pyridines / therapeutic use. Pyrroles / therapeutic use. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Sirolimus / analogs & derivatives. Sirolimus / therapeutic use. TOR Serine-Threonine Kinases. Vascular Endothelial Growth Factor A / antagonists & inhibitors. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20418205.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Benzenesulfonates; 0 / Cytokines; 0 / Indoles; 0 / Interferon-alpha; 0 / Intracellular Signaling Peptides and Proteins; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 0 / Pyrroles; 0 / Vascular Endothelial Growth Factor A; 0 / sunitinib; 25X51I8RD4 / Niacinamide; 2S9ZZM9Q9V / Bevacizumab; 624KN6GM2T / temsirolimus; 9ZOQ3TZI87 / sorafenib; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


36. Fottner A, Szalantzy M, Wirthmann L, Stähler M, Baur-Melnyk A, Jansson V, Dürr HR: Bone metastases from renal cell carcinoma: patient survival after surgical treatment. BMC Musculoskelet Disord; 2010;11:145
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone metastases from renal cell carcinoma: patient survival after surgical treatment.
  • BACKGROUND: Surgery is the primary treatment of skeletal metastases from renal cell carcinoma, because radiation and chemotherapy frequently are not effecting the survival.
  • We therefore explored factors potentially affecting the survival of patients after surgical treatment.
  • METHODS: We retrospectively reviewed 101 patients operatively treated for skeletal metastases of renal cell carcinoma between 1980 and 2005.
  • RESULTS: 27 patients had a solitary bone metastasis, 20 patients multiple bone metastases and 54 patients had concomitant visceral metastases.
  • Patients with solitary bone metastases had a better survival (p < 0.001) compared to patients with multiple metastases.
  • Age younger than 65 years (p = 0.036), absence of pathologic fractures (p < 0.001) and tumor-free resection margins (p = 0.028) predicted higher survival.
  • Gender, location of metastases, time between diagnosis of renal cell carcinoma and treatment of metastatic disease, incidence of local recurrence, radiation and chemotherapy did not influence survival.
  • CONCLUSIONS: The data suggest that patients with a solitary metastasis or a limited number of resectable metastases are candidates for wide resections.
  • As radiation and chemotherapy are ineffective in most patients, surgery is a better option to achieve local tumor control and increase the survival.
  • [MeSH-major] Bone Neoplasms / mortality. Bone Neoplasms / secondary. Carcinoma, Renal Cell / mortality. Carcinoma, Renal Cell / secondary. Kidney Neoplasms / secondary
  • [MeSH-minor] Age Distribution. Age Factors. Aged. Disease Progression. Female. Fractures, Bone / epidemiology. Fractures, Bone / pathology. Fractures, Bone / physiopathology. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / physiopathology. Neoplasm Recurrence, Local / prevention & control. Neoplasm Recurrence, Local / surgery. Prognosis. Retrospective Studies. Severity of Illness Index. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Z Orthop Ihre Grenzgeb. 2006 Jan-Feb;144(1):58-67 [16498562.001]
  • [Cites] Cancer. 2005 Nov 1;104(9):1894-900 [16177996.001]
  • [Cites] Clin Orthop Relat Res. 2007 Jun;459:133-8 [17438472.001]
  • [Cites] J Bone Joint Surg Am. 2007 Aug;89(8):1794-801 [17671020.001]
  • [Cites] Clin Orthop Relat Res. 1999 Oct;(367):283-90 [10546626.001]
  • [Cites] J Bone Joint Surg Br. 2000 Jan;82(1):62-7 [10697316.001]
  • [Cites] Semin Oncol. 2000 Apr;27(2):115-23 [10768591.001]
  • [Cites] Semin Oncol. 2000 Apr;27(2):160-76 [10768595.001]
  • [Cites] J Urol. 2000 Nov;164(5):1505-8 [11025692.001]
  • [Cites] Int J Oncol. 2001 Aug;19(2):379-82 [11445855.001]
  • [Cites] J Bone Joint Surg Br. 2002 May;84(4):521-9 [12043772.001]
  • [Cites] Urology. 2003 Feb;61(2):314-9 [12597937.001]
  • [Cites] Clin Orthop Relat Res. 2003 Apr;(409):223-31 [12671506.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3316-22 [15310775.001]
  • [Cites] Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6302S-3S [15448021.001]
  • [Cites] J Urol. 1975 Jul;114(1):27-9 [1142493.001]
  • [Cites] Urology. 1978 Jun;11(6):563-7 [675922.001]
  • [Cites] Clin Orthop Relat Res. 1980 Nov-Dec;(153):106-20 [7449206.001]
  • [Cites] Urology. 1981 Dec;18(6):556-61 [7314355.001]
  • [Cites] Acta Orthop Scand. 1984 Oct;55(5):491-500 [6507069.001]
  • [Cites] J Urol. 1988 Aug;140(2):277-9 [3398121.001]
  • [Cites] Jpn J Clin Oncol. 1989 Jun;19(2):142-8 [2733167.001]
  • [Cites] J Surg Oncol. 1992 Jan;49(1):45-8 [1548881.001]
  • [Cites] J Urol. 1992 Sep;148(3):784-7 [1512825.001]
  • [Cites] Cancer. 1997 Sep 15;80(6):1103-9 [9305711.001]
  • [Cites] JAMA. 1999 May 5;281(17):1628-31 [10235157.001]
  • [Cites] Scand J Urol Nephrol. 2004;38(4):299-305 [15669589.001]
  • [Cites] Clin Orthop Relat Res. 2005 Feb;(431):187-92 [15685074.001]
  • [Cites] Eur Urol. 2007 Jul;52(1):163-8 [17098353.001]
  • (PMID = 20598157.001).
  • [ISSN] 1471-2474
  • [Journal-full-title] BMC musculoskeletal disorders
  • [ISO-abbreviation] BMC Musculoskelet Disord
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2909163
  •  go-up   go-down


37. Miwa S, Kadono Y, Sugata T, Mizokami A, Namiki M: Successful treatment for metastases from renal cell carcinoma with alternation of interferon-alpha subtypes. Int J Clin Oncol; 2010 Feb;15(1):97-100
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment for metastases from renal cell carcinoma with alternation of interferon-alpha subtypes.
  • Here we present a case in which alternation of interferon-alpha (IFN-alpha) treatments was effective in treating pulmonary metastases and lymph node metastases from renal cell carcinoma (RCC).
  • A 56-year-old man underwent left radical nephrectomy under the diagnosis of left RCC.
  • The histological diagnosis was clear cell carcinoma G2, IFN-alpha, pT1b.
  • He subsequently underwent two operations for right pulmonary metastasis and right hilar lymph node metastasis.
  • However, multiple pulmonary metastases and left hilar lymph node metastasis occurred 11 months after discontinuation of Sumiferon.
  • Therefore, treatment with another natural IFN-alpha (OIF) was started.
  • Although OIF was continued for 7 months, pulmonary metastases and left hilar lymph node metastasis continued to progress.
  • Therefore, treatment was changed to Sumiferon, after which the pulmonary metastases and left hilar lymph node metastasis decreased in size.
  • The metastases showed no progression for 16 months after switching from OIF to Sumiferon.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Interferon-alpha / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lymphatic Metastasis
  • [MeSH-minor] Drug Administration Schedule. Humans. Kidney Neoplasms / drug therapy. Kidney Neoplasms / pathology. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Interferon Cytokine Res. 1999 Dec;19(12 ):1343-9 [10638703.001]
  • [Cites] Nihon Hinyokika Gakkai Zasshi. 2004 Jan;95(1):50-3 [14978941.001]
  • [Cites] Nihon Hinyokika Gakkai Zasshi. 2006 Mar;97(3):598-601 [16613162.001]
  • [Cites] Int J Urol. 2008 Sep;15(9):848-50 [18786206.001]
  • [Cites] J Interferon Cytokine Res. 2001 Dec;21(12):1129-36 [11798471.001]
  • [Cites] Biomed Res. 2005 Jun;26(3):135-7 [16011307.001]
  • [Cites] Int J Oncol. 2006 Apr;28(4):965-70 [16525647.001]
  • [Cites] Ann Thorac Surg. 1994 Feb;57(2):339-44 [8311594.001]
  • (PMID = 20066455.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Interferon-alpha
  •  go-up   go-down


38. Miron L, Ciornea L: [Renal cancer :therapeutical dilemma]. Rev Med Chir Soc Med Nat Iasi; 2001 Jul-Sep;105(3):475-80
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Renal cancer :therapeutical dilemma].
  • [Transliterated title] Cancerul renal--dilema opţiunilor terapeutice!
  • Renal cell carcinoma constitutes 3% of all adult malignancies.
  • Surgical resection remains the cornerstone of management for localised renal cell carcinoma.
  • No effective postsurgical adjuvant therapy has been established for patients with locally advanced disease who are a high risk for recurrence.
  • The effective treatment of metastatic kidney cancer remains a challenge.
  • Despite extensive investigations with different treatment modalities, metastatic renal cell carcinoma remains high resistant to systemic therapy.
  • Combination chemotherapy alone or in combination with cytokine, is a very little use.
  • New immunologic approaches to the treatment of both advanced and high-risk postsurgical disease are focusing on novel vaccine therapies to target both renal epithelial and vascular antigens.
  • [MeSH-major] Carcinoma, Renal Cell / therapy. Kidney Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Humans. Interferon-alpha / administration & dosage. Interleukin-2 / administration & dosage. Nephrectomy / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Kidney cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12092176.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Interleukin-2
  • [Number-of-references] 10
  •  go-up   go-down


39. Ho L, Wassef H, Henderson R, Seto J: Renal metastasis from primary colon cancer on FDG PET-CT. Clin Nucl Med; 2009 Sep;34(9):596-7
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal metastasis from primary colon cancer on FDG PET-CT.
  • We report the PET-CT appearance of a metastasis from a primary colon cancer to the right kidney in an 84-year-old woman with a history of moderately differentiated adenocarcinoma of the cecum.
  • The patient underwent right hemicolectomy and chemotherapy.
  • Restaging PET-CT study, 4 months after her last chemotherapy, demonstrates a hypermetabolic soft-tissue mass in the inferior pole of the right kidney.
  • The pathology was consistent with metastatic colonic adenocarcinoma.
  • Renal metastasis from primary colon cancer is very rare.
  • [MeSH-major] Colonic Neoplasms / pathology. Colonic Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Kidney Neoplasms / radionuclide imaging. Kidney Neoplasms / secondary
  • [MeSH-minor] Aged, 80 and over. Female. Humans. Positron-Emission Tomography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Kidney cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19692821.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


40. Koutras AK, Krikelis D, Alexandrou N, Starakis I, Kalofonos HP: Brain metastasis in renal cell cancer responding to sunitinib. Anticancer Res; 2007 Nov-Dec;27(6C):4255-7
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain metastasis in renal cell cancer responding to sunitinib.
  • BACKGROUND: Sunitinib (SU011248; Sutent) is a new small molecule that inhibits members of the split-kinase domain family of receptor tyrosine kinases (RTKs), with established antitumor activity in renal cancer.
  • In the current report, we describe a patient with a solitary brain metastasis from renal cell carcinoma who achieved partial response of the cerebral lesion following treatment with sunitinib.
  • To the best of our knowledge, this is the first report of sunitinib activity in brain metastases from kidney cancer.
  • Although the role of sunitinib in advanced renal carcinoma has been evaluated through prospective trials, the efficacy of the drug in patients with brain metastases has not been explored, since patients with cerebral lesions were excluded in those studies.
  • Moreover, in our case, sunitinib was found to be safe, leading to considerable shrinkage of the brain metastasis without any serious adverse events or central nervous system toxicities.
  • We consider this observation to be important, given the absence of data regarding the activity of the drug in this particular clinical setting.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Carcinoma, Renal Cell / secondary. Indoles / therapeutic use. Kidney Neoplasms / pathology. Pyrroles / therapeutic use
  • [MeSH-minor] Adult. Female. Humans. Interferon-alpha / therapeutic use. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18214028.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Indoles; 0 / Interferon-alpha; 0 / Pyrroles; 0 / sunitinib
  •  go-up   go-down


41. Sakamoto LH, Mendes W, Pecora M, Andrade RG, Begnani MD, de Camargo B: Bilateral renal metastases from osteosarcoma: A case report and review of the literature. J Pediatr Hematol Oncol; 2006 Sep;28(9):618-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral renal metastases from osteosarcoma: A case report and review of the literature.
  • Improvements in multimodal therapy for osteosarcoma (OS) have increased event-free and overall survival.
  • We report a young adult with OS who developed late bilateral renal relapse.
  • Late recurrences to the kidneys have a more aggressive clinical behavior and poor prognosis documented by 15 cases of OS metastastic to the kidney in the literature.
  • Two of those patients had a long survival after chemotherapy and surgery.
  • This suggests that the disease can be controlled with early detection and treatment.
  • [MeSH-major] Bone Neoplasms / pathology. Kidney Neoplasms / secondary. Osteosarcoma / secondary
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Male. Tibia / pathology

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17006269.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Ulmar B, Catalkaya S, Naumann U, Gerstner S, Cakir B, Schmidt R, Reichel H, Huch K: [Surgical treatment and evaluation of prognostic factors in spinal metastases of renal cell carcinoma]. Z Orthop Ihre Grenzgeb; 2006 Jan-Feb;144(1):58-67
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment and evaluation of prognostic factors in spinal metastases of renal cell carcinoma].
  • [Transliterated title] Chirurgische Therapie und Evaluation von Prognosefaktoren bei Wirbelsäulenmetastasen durch Nieren-Zell-Karzinome.
  • AIM: The aim of this study was the evaluation of surgical results and prognostic factors in spinal metastases of renal cancer.
  • METHODS: 37 surgical patients with spinal metastases of renal cell carcinoma were retrospectively analysed.
  • In 2 patients the cervical, in 16 patients the thoracic, in 4 patients the thoraco-lumbar and in 16 patients the lumbar spine was involved.
  • For the postoperative survival the Karnofsky-Index and the Frankel-Score were univariate highly significant, the factors nutritional condition and latency between the primary tumor and the development of spinal metastases showed a lower significancy.
  • No prognostical influence for the postoperative survival could be detected for the factors gender, age, localisation of the metastases, type of operation and the factor solitary/multiple metastases.
  • The postoperative survival was significantly (p: 0.0030) influenced by postoperative adjuvant therapy (radio- and/or chemotherapy).
  • The analysis of each adjuvant therapy form (i. e. chemo-, radio- and combined therapy) attempts this prognostic effect (p: 0.0229).
  • CONCLUSION: In most patients with spinal metastases of renal cell carcinoma, the singular posterior intrumentation combined with a decompression is a sufficient therapy.
  • The prognostic influence of an adjuvant postoperative treatment in the present study must be interpreted in the context of this small, highly selected patient collective.
  • Further standardized studies should be performed to evaluate the prognostic influence of an adjuvant therapy.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Kidney Neoplasms / surgery. Spinal Neoplasms / secondary

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16498562.001).
  • [ISSN] 0044-3220
  • [Journal-full-title] Zeitschrift für Orthopädie und ihre Grenzgebiete
  • [ISO-abbreviation] Z Orthop Ihre Grenzgeb
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


43. Lümmen G, Schenck M, Börgermann C, Eisenhardt A, Vom Dorp F, Sperling H, Rübben H: [Inhaled immunotherapy for pulmonary metastases of renal cell cancer]. Urologe A; 2004 Apr;43(4):457-61
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Inhaled immunotherapy for pulmonary metastases of renal cell cancer].
  • Studies on immunotherapy with inhaled interleukin-2 (IL-2) for the treatment of pulmonary metastases in renal cell carcinoma patients have indicated objective response rates of 11%.
  • Patients with pulmonary metastases of renal cell carcinoma were treated with interferon-alpha (IFN-alpha) 3 x 10(6) IU/m(2) s.c. on days 1, 3, and 5 and inhaled twice a day 9 x 10(6) IU IL-2 on days 1-5.
  • Treatment continued for 4 weeks and after a 2-week rest a second cycle was given.
  • Quality of life was assessed according a self-administered quality of life questionnaire (QLQ-C30) before, during, and after therapy.
  • Sixteen patients had pulmonary metastases only and five patients additionally had bone or liver metastasis or local recurrence.
  • One patient (5%) developed a partial remission for 4 months and ten patients (47.5%) showed a stable disease for a median time of 6 months (2-24 months).
  • Ten patients (47.5%) developed progressive disease.
  • The patients' quality of life did not change significantly at any time during therapy.
  • Inhaled immunotherapy is a treatment option with little toxicity, but achieved only a few objective responses.
  • [MeSH-major] Carcinoma, Renal Cell / drug therapy. Carcinoma, Renal Cell / secondary. Immunotherapy / methods. Interleukin-2 / administration & dosage. Kidney Neoplasms / drug therapy. Kidney Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary
  • [MeSH-minor] Administration, Inhalation. Adult. Aged. Antineoplastic Agents / administration & dosage. Humans. Male. Middle Aged. Quality of Life. Treatment Outcome

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1996 Jul;2(7):1115-22 [9816276.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):497-501 [7844611.001]
  • [Cites] Urology. 1993 Jan;41(1 Suppl):67-72 [7678365.001]
  • [Cites] Tumori. 1993 Dec 31;79(6):397-400 [8171738.001]
  • [Cites] J Urol. 1983 Dec;130(6):1063-6 [6644883.001]
  • [Cites] JAMA. 1999 May 5;281(17):1628-31 [10235157.001]
  • [Cites] Urol Clin North Am. 1993 May;20(2):283-95 [7684167.001]
  • [Cites] J Urol. 1995 Jul;154(1):28-31 [7776446.001]
  • [Cites] Urologe A. 1999 Sep;38(5):466-73 [10501705.001]
  • [Cites] J Clin Oncol. 1993 Apr;11(4):661-70 [8478661.001]
  • [Cites] Pharmacol Res. 1998 Sep;38(3):151-64 [9782064.001]
  • [Cites] Int J Cancer. 1993 Dec 2;55(6):891-903 [8253525.001]
  • [Cites] Cancer J Sci Am. 1997 May-Jun;3(3):157-62 [9161781.001]
  • [Cites] N Engl J Med. 1998 Apr 30;338(18):1272-8 [9562581.001]
  • [Cites] J Cancer Res Clin Oncol. 1995;121(5):285-90 [7768966.001]
  • [Cites] Eur Urol. 2001 Feb;39(2):121-30 [11223670.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] J Cancer Res Clin Oncol. 1994;120(4):221-8 [8288676.001]
  • [Cites] J Urol. 1992 Feb;147(2):344-8 [1732590.001]
  • [Cites] J Urol. 1996 Feb;155(2):455-8 [8558634.001]
  • [Cites] J Clin Oncol. 1993 Sep;11(9):1809-16 [8355047.001]
  • (PMID = 15085267.001).
  • [ISSN] 0340-2592
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interleukin-2
  •  go-up   go-down


44. Esteban-González E, Carballido J, Navas V, Torregrosa Z, Muñoz A, de Mon MA, PortugueseSpanish Inhaled IL-2 Group: Retrospective review in patients with pulmonary metastases of renal cell carcinoma receiving inhaled recombinant interleukin-2. Anticancer Drugs; 2007 Mar;18(3):291-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective review in patients with pulmonary metastases of renal cell carcinoma receiving inhaled recombinant interleukin-2.
  • Pulmonary metastases of renal cell carcinoma are associated with poor prognosis.
  • Systemic interleukin-2 is used to treat pulmonary metastases of renal cell carcinoma; however, its toxicity limits its use.
  • The objective of this study was to evaluate the efficacy and safety of inhaled interleukin-2 in pulmonary metastases of renal cell carcinoma patients.
  • The study was designed as a retrospective chart review in pulmonary metastases of renal cell carcinoma patients treated with inhaled interleukin-2.
  • The treatment schedule was as follows: three cycles of 36 MIU interleukin-2 per day for 5 days/week for 12 weeks (with 1 treatment-free week between cycles) in Spain and for 3 weeks (out of each 4 weeks) for 12 weeks in Portugal.
  • Efficacy was assessed by best response following each treatment cycle and at final evaluation.
  • The majority of weeks of toxicities were reported to be only grade 1 or 2 in severity.
  • Inhaled interleukin-2 shows efficacy and mild toxicity of pulmonary metastases of renal cell carcinoma patients, and might be considered as an alternative treatment to the systemic administration of this drug in these patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Renal Cell / drug therapy. Interleukin-2 / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Lung Neoplasms / secondary
  • [MeSH-minor] Administration, Inhalation. Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Male. Middle Aged. Recombinant Proteins / administration & dosage. Recombinant Proteins / adverse effects. Recombinant Proteins / therapeutic use. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17264761.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interleukin-2; 0 / Recombinant Proteins
  •  go-up   go-down


45. Salminen E, Kankuri M, Nuutila J, Lilius EM, Pellimiemi TT: Modulation of IgG and complement receptor expression of phagocytes in kidney cancer patients during treatment with interferon-alpha. Anticancer Res; 2001 May-Jun;21(3B):2049-55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modulation of IgG and complement receptor expression of phagocytes in kidney cancer patients during treatment with interferon-alpha.
  • BACKGROUND: The mode of action of interferon involves both direct cytotoxic and antiproliferative effects on the tumour cell and indirect effects that facilitate immune detection by the host.
  • We hypothesised that the role of phagocytes in defence against cancer is reflected in the expression of opsonin receptors for IgG and complement, which further could be modified by INF-alpha.
  • PATIENTS AND METHODS: The expression of the receptors for IgG and complement was studied in neutrophils and monocytes from blood samples of 18 kidney cancer patients treated with INF-alpha and from 39 healthy individuals.
  • Blood samples were collected prior/to and during treatment with INF-alpha, 4.5 to 13.5 MU t.d.w., subcutaneously.
  • RESULTS: In patients before any treatment, the expression of CR3 and Fc gammaRI receptors in neutrophils and all receptors except Fc gammaRIII in monocytes was significantly raised when compared to the controls.
  • Treatment with INF-alpha, induced statistically significant; transient changes in CR1-receptor expression in neutrophils and Fc gammaRI expression in monocytes.
  • CONCLUSION: Changes in receptor expression reflect the inflammatory activation of phagocytes in metastatic kidney cancer.
  • [MeSH-major] Immunoglobulin G / metabolism. Interferon-alpha / metabolism. Kidney Neoplasms / drug therapy. Kidney Neoplasms / immunology. Phagocytes / metabolism. Receptors, Complement / metabolism
  • [MeSH-minor] Aged. Antibodies, Monoclonal / metabolism. Dose-Response Relationship, Drug. Female. Flow Cytometry. Humans. Immunoglobulin Fragments / metabolism. Kinetics. Male. Middle Aged. Monocytes / metabolism. Phagocytosis. Receptors, Immunologic / blood. Time Factors

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11497297.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Immunoglobulin Fragments; 0 / Immunoglobulin G; 0 / Interferon-alpha; 0 / Receptors, Complement; 0 / Receptors, Immunologic; 0 / opsonin receptor
  •  go-up   go-down


46. Alexandrescu DT, Dasanu CA: Kidney cancer therapy: new perspectives and avenues. Expert Opin Pharmacother; 2006 Dec;7(18):2481-93
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kidney cancer therapy: new perspectives and avenues.
  • Immunotherapy with interleukin-2 and interferon-alpha has been the only viable option in metastatic renal cell cancer for almost two decades.
  • In the last several years, significant advances in the understanding of the underlying biological and molecular mechanisms of renal cell carcinoma, particularly the role of tumour angiogenesis, have led to the identification of rational therapeutic targets and permitted the design of molecularly targeted therapeutics.
  • The use of small molecules, such as multitargeted tyrosine kinase inhibitors, the mTOR inhibitors and monoclonal antibodies, is dramatically changing the existing concepts of systemic treatment for metastatic kidney cancer.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Renal Cell / drug therapy. Drug Delivery Systems / trends. Kidney Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17150003.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 86
  •  go-up   go-down


47. Weber KL, Doucet M, Price JE: Renal cell carcinoma bone metastasis: epidermal growth factor receptor targeting. Clin Orthop Relat Res; 2003 Oct;(415 Suppl):S86-94
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal cell carcinoma bone metastasis: epidermal growth factor receptor targeting.
  • Renal cell carcinoma frequently metastasizes to the skeleton in the later stages of the disease.
  • Patients with bone metastasis from renal cell carcinoma experience severe pain, neurologic compromise, and frequent pathologic fractures.
  • These tumors are relatively resistant to chemotherapy and radiation, and the 5-year survival of patients is less than 10%.
  • The epidermal growth factor receptor is overexpressed in human renal cell carcinoma and hypothesized to be a potential target in the treatment of bone metastasis.
  • Using in vitro studies, it was shown that blockade of the epidermal growth factor receptor was effective in decreasing proliferation and receptor autophosphorylation of a human bone-derived renal cell carcinoma cell line.
  • In an experimental nude mouse model, treatment with Taxol and protein tyrosine kinase inhibitor 166, a small molecule receptor tyrosine kinase inhibitor, blocked the growth of renal cell carcinoma in the tibia and resulted in decreased bone destruction.
  • Epidermal growth factor receptor blockade is an exciting potential therapy for renal cell carcinoma bone metastasis in humans, but because it is cytostatic rather than cytotoxic, its optimal role may be as a supplement to cytotoxic chemotherapy.
  • It ultimate role and its relationship to other therapeutic interventions remains to be elucidated and validated.
  • [MeSH-major] Bone Neoplasms / secondary. Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology. Pyrimidines / pharmacology. Pyrroles / pharmacology. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, Epidermal Growth Factor / physiology
  • [MeSH-minor] Animals. Antineoplastic Agents, Phytogenic / pharmacology. Mice. Mice, Nude. Paclitaxel / pharmacology. Phosphorylation. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14600596.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16672
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / PKI 166; 0 / Pyrimidines; 0 / Pyrroles; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


48. Filippetti M, Torsello A, Cordiali Fei P, Bordignon V, Trento E, Tonachella R, Piperno G, Prignano G: [IL-2 bronchoscopic istillation and immune cell activation: preliminary results of the BRIIL-2 study for treatment of pulmonary metastasis from renal cancer and melanoma]. Clin Ter; 2009;160(2):139-43
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [IL-2 bronchoscopic istillation and immune cell activation: preliminary results of the BRIIL-2 study for treatment of pulmonary metastasis from renal cancer and melanoma].
  • [Transliterated title] Broncoistillazione diretta di IL-2 in fibrobroncoscopia e attivazione immunitaria: risultati preliminari dello studio clinico BRIIL-2 sul trattamento delle metastasi polmonari da neoplasia renale e melanoma.
  • BRIIL-2 is a clinical study for evaluation of efficacy and toxicity of third line treatment of pulmonary metastasis from renal cancer and melanoma with flexible bronchoscopic istillation of IL-2.
  • Up today we enrolled two patients with pulmonary metastasis from renal cancer already treated with two lines of molecular therapy, chemotherapy or systemic immunotherapy.
  • Regarding to immunologic stimulation, lymphocytic fraction decreased from 21 to 2% in the first and from 10.5 to 6% in the second patient, indicating lymphocytic enrollment for activation, while TCD4/CD8 ratio is stable.
  • In both patients we also observed a significant increase of HLA-DR in T lymphocytes (CD3) either in BAL or in peripheral blood.
  • [MeSH-major] Bronchoscopy. Carcinoma, Renal Cell / secondary. Interleukin-2 / therapeutic use. Kidney Neoplasms / pathology. Lung Neoplasms / secondary. T-Lymphocytes / drug effects
  • [MeSH-minor] Bone Neoplasms / secondary. Bone Neoplasms / therapy. Bronchoalveolar Lavage Fluid / cytology. Combined Modality Therapy. Female. Fiber Optic Technology. HLA-DR Antigens / biosynthesis. HLA-DR Antigens / genetics. Humans. Instillation, Drug. Lymphocyte Activation / drug effects. Lymphocyte Count. Lymphocyte Subsets / drug effects. Lymphocyte Subsets / immunology. Lymphocyte Subsets / metabolism. Male. Melanoma / secondary. Melanoma / therapy. Middle Aged. Nephrectomy

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19452104.001).
  • [ISSN] 1972-6007
  • [Journal-full-title] La Clinica terapeutica
  • [ISO-abbreviation] Clin Ter
  • [Language] ita
  • [Publication-type] Case Reports; Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / HLA-DR Antigens; 0 / Interleukin-2
  •  go-up   go-down


49. Kamiński B, Kobiorska-Nowak J, Bień S: [Distant metastases to nasal cavities and paranasal sinuses, from the organs outside the head and neck]. Otolaryngol Pol; 2008;62(4):422-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Distant metastases to nasal cavities and paranasal sinuses, from the organs outside the head and neck].
  • INTRODUCTION: The metastases from below the clavicles, to the head and neck region, are relatively uncommon, and usually demonstrate during the progression of the primary disease.
  • At that time, the correct diagnosis requires only to compare the pathology report from the primary biopsy, with the biopsy from the lump in the head and neck.
  • The majority of distant metastases to the head and neck region are localized within the lymph nodes.
  • The metastases to nasal cavity and paranasal sinuses are very rare and usually localized within the maxillary sinus.
  • MATERIAL: 4 cases, out of 46 all distant metastases to the head and neck region, localized in the nasal cavity and paranasal sinuses, diagnosed and treated in Dept. of ORL H&N surgery, Holy Cross Cancer Centre, from 2001 to 2007.
  • Case I. F. 71 years; the metastasis of colonic carcinoma to the sphenoid sinus as a first symptom of the disease).
  • The palliative Rtg-therapy was applied, and patient died in 2 months after diagnosis was established.
  • Case II. M. 69 y with metastasis of kidney cancer (Ca clarocellulare) to the nasal cavity, during a palliative stage of the disease due to multiple lung metastases.
  • Patient was treated with multiple courses of chemotherapy due to generalization of the disease.
  • The nasal cavity metastasis was treated with repeated local resections.
  • At present with no metastasis within the head and neck region--alive, in relatively good condition, with 23 months of observation.
  • Cases III. F. 50 years in palliative stage of the breast cancer, with metastases to the bones and hepar and with metastasis to the maxillary sinus.
  • Received palliative Rtg. therapy on the region of metastasis.
  • Died in 5 months after diagnosis of maxillary sinus metastasis.
  • Case IV. F. 54 years in palliative stage of the colonic cancer, with multiple metastases to the lungs and hepar; with metastasis to the maxillary sinus.
  • During hemotherapy a symptoms of tumor of the maxillary sinus appeared, confirmed as a metastasis.
  • The palliative Rtg-therapy on the region of metastasis.
  • Died in 18 months, after diagnosis of maxillary sinus metastasis.
  • CONCLUSIONS: The prognosis of metastases from distant organs, to the nasal cavity and paranasal sinuses is miserable.
  • In the majority of distant metastases to the nose and paranasal sinuses, the palliative therapy is the only possible option of treatment.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Carcinoma, Renal Cell / pathology. Colonic Neoplasms / pathology. Paranasal Sinus Neoplasms / secondary. Skull Base Neoplasms / secondary
  • [MeSH-minor] Aged. Female. Humans. Male. Middle Aged. Poland. Prognosis. Survival Analysis. Treatment Failure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18837216.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


50. Coutts MA, Borthwick NJ, Hungerford JL, Cree IA: Post-menopausal bleeding: a rare presentation of metastatic uveal melanoma. Pathol Oncol Res; 2006;12(3):184-7
MedlinePlus Health Information. consumer health - Vaginal Bleeding.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-menopausal bleeding: a rare presentation of metastatic uveal melanoma.
  • Uveal melanoma differs from cutaneous melanoma in many ways, including its pattern of metastasis, and exhibits latency with clinical evidence of metastasis sometimes appearing many years after primary diagnosis.
  • Most patients develop metastasis within the liver, but some may present with metastasis to other sites.
  • We report a case of uveal melanoma that presented with post-menopausal bleeding due to metastasis.
  • Further investigation revealed widespread metastatic disease and the patient was not fit for chemotherapy.
  • She died two months after presentation: autopsy revealed metastases in many sites, including the uterus, right ovarian fibroma, kidney, mesentery, liver, lung, thyroid, bone marrow and skin.
  • The immediate cause of death was cardiac tamponade due to a malignant effusion secondary to cardiac metastasis.
  • This case illustrates the widespread metastatic potential of uveal melanoma and highlights the potential for unusual presentation of metastatic disease from this eye tumor.
  • [MeSH-minor] Aged, 80 and over. Endometrial Neoplasms / secondary. Female. Heart Neoplasms / secondary. Humans. Liver Neoplasms / secondary. Neoplasm Metastasis. Postmenopause

  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Ophthalmol (Copenh). 1970;48(6):1113-28 [5537253.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2003 Nov;44(11):4651-9 [14578381.001]
  • [Cites] Am J Ophthalmol. 1985 Nov 15;100(5):666-8 [4061546.001]
  • [Cites] Retina. 1981;1(2):100-6 [7348822.001]
  • [Cites] Gynecol Oncol. 2004 Apr;93(1):252-6 [15047246.001]
  • [Cites] Am J Ophthalmol. 1978 Oct;86(4):557-64 [707604.001]
  • [Cites] Cancer. 1982 Nov 15;50(10):2163-9 [7127256.001]
  • [Cites] J Thorac Cardiovasc Surg. 2005 Dec;130(6):1727-8 [16308029.001]
  • [Cites] Acta Ophthalmol (Copenh). 1963;43:SUPPL 75:1-220 [14050563.001]
  • [Cites] J Med Ethics. 2005 Jun;31(6):360-1 [15923487.001]
  • [Cites] J Med Ethics. 2004 Dec;30(6):561-4 [15574445.001]
  • [Cites] Ophthalmology. 1980 Jun;87(6):549-56 [7413144.001]
  • [Cites] Acta Ophthalmol (Copenh). 1982 Apr;60(2):161-82 [7136531.001]
  • [Cites] Int Ophthalmol. 1985 Mar;7(3-4):175-81 [3997359.001]
  • [Cites] Br J Ophthalmol. 1999 May;83(5):588-94 [10216060.001]
  • [Cites] Arch Ophthalmol. 1999 Nov;117(11):1558-9 [10565531.001]
  • [Cites] Cancer Invest. 1997;15(2):98-105 [9095204.001]
  • [Cites] Acta Cytol. 1978 Nov-Dec;22(6):503-6 [282750.001]
  • [Cites] Chest. 2001 Dec;120(6):2115 [11742953.001]
  • [Cites] APMIS. 1989 Nov;97(11):1018-24 [2590533.001]
  • [Cites] Cancer. 1974 Mar;33(3):729-31 [4815575.001]
  • (PMID = 16998600.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


51. Morais C, Pat B, Gobe G, Johnson DW, Healy H: Pyrrolidine dithiocarbamate exerts anti-proliferative and pro-apoptotic effects in renal cell carcinoma cell lines. Nephrol Dial Transplant; 2006 Dec;21(12):3377-88
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pyrrolidine dithiocarbamate exerts anti-proliferative and pro-apoptotic effects in renal cell carcinoma cell lines.
  • BACKGROUND: The activation of nuclear factor-kappaB (NF-kappaB) has been implicated in the development, progression and metastasis of renal cell carcinoma (RCC).
  • This study investigates the effect of pyrrolidine dithiocarbamate (PDTC), a NF-kappaB inhibitor, on two metastatic human RCC cell lines, ACHN and SN12K1.
  • [MeSH-major] Apoptosis / drug effects. Carcinoma, Renal Cell / drug therapy. Carcinoma, Renal Cell / pathology. Cell Proliferation / drug effects. Kidney Neoplasms / drug therapy. Kidney Neoplasms / pathology. NF-kappa B / antagonists & inhibitors. Pyrrolidines / therapeutic use. Thiocarbamates / therapeutic use
  • [MeSH-minor] Cell Line, Tumor. Humans

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16998220.001).
  • [ISSN] 0931-0509
  • [Journal-full-title] Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • [ISO-abbreviation] Nephrol. Dial. Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / NF-kappa B; 0 / Pyrrolidines; 0 / Thiocarbamates; 25769-03-3 / pyrrolidine dithiocarbamic acid
  •  go-up   go-down


52. Pfannschmidt J, Geisbüsch P, Muley T, Hoffmann H, Dienemann H: Surgical resection of secondary chest wall tumors. Thorac Cardiovasc Surg; 2005 Aug;53(4):234-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical resection of secondary chest wall tumors.
  • OBJECTIVE: The objective of this study was to evaluate which factors influence survival following surgical resection of secondary tumors of the chest wall (non-bronchial carcinoma).
  • All of the patients were retrospectively analyzed for sex and age, presenting symptoms, tumor location, disease-free interval, histology, radiation therapy or chemotherapy, surgical techniques and extent of resection, 30-day mortality and long-term survival.
  • RESULTS: The most common tumors were isolated locally recurrent breast cancer (n = 33) and renal cell carcinoma (n = 17).
  • In patients with isolated recurrence of breast cancer and in patients with chest wall metastases of renal cell cancer, the median survival was 40.6 months and 53.7 months, respectively.
  • A disease-free interval of more than 24 months and no systemic chemotherapy after mastectomy were parameters for a favorable prognosis in patients with breast cancer.
  • CONCLUSIONS: We conclude that chest wall resection of secondary chest wall tumors is a safe and effective treatment as part of a multidisciplinary approach.
  • The role of surgery will continue to evolve as improvements in systemic treatment occur.
  • [MeSH-major] Neoplasm Recurrence, Local / surgery. Thoracic Neoplasms / secondary. Thoracic Neoplasms / surgery. Thoracic Surgical Procedures / methods. Thoracic Wall / surgery
  • [MeSH-minor] Adult. Age Factors. Aged. Cohort Studies. Female. Humans. Male. Middle Aged. Neoplasm Staging. Probability. Prognosis. Retrospective Studies. Risk Assessment. Sex Factors. Statistics, Nonparametric. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16037870.001).
  • [ISSN] 0171-6425
  • [Journal-full-title] The Thoracic and cardiovascular surgeon
  • [ISO-abbreviation] Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


53. Oya M, Asakura H, Mizuno R, Marumo K, Murai M: Repeated regression of pulmonary metastases from renal cell carcinoma after treatment using different interferon-alpha preparations. Biomed Res; 2005 Jun;26(3):135-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Repeated regression of pulmonary metastases from renal cell carcinoma after treatment using different interferon-alpha preparations.
  • A 49-year-old man with pulmonary metastasis from renal cell carcinoma (RCC) was treated with recombinant IFN-alpha2b (Intron A).
  • A complete response was achieved within 4 months and thereafter persisted for 5 years until he developed another lung lesion.
  • The pulmonary lesion achieved a partial response after 11 months of treatment.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinoma, Renal Cell / drug therapy. Interferon-alpha / pharmacology. Kidney Neoplasms / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Humans. Immunotherapy. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16011307.001).
  • [ISSN] 0388-6107
  • [Journal-full-title] Biomedical research (Tokyo, Japan)
  • [ISO-abbreviation] Biomed. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha
  •  go-up   go-down


54. Stage AC, Pollock RE, Matin SF: Bilateral metastatic renal synovial sarcoma. Urology; 2005 Feb;65(2):389
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral metastatic renal synovial sarcoma.
  • Synovial sarcoma is a malignant soft-tissue neoplasm, usually arising in close association with the joints and generally carrying a poor prognosis.
  • We describe the first report of bilateral renal metastases from synovial sarcoma in a long-term survivor.
  • Treatment consisted of systemic therapy with bilateral partial nephrectomies.
  • [MeSH-major] Forearm. Kidney Neoplasms / secondary. Sarcoma, Synovial / secondary. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Amputation. Antineoplastic Agents, Alkylating / therapeutic use. Combined Modality Therapy. Female. Humans. Ifosfamide / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Middle Aged. Nephrectomy / methods

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15708068.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; UM20QQM95Y / Ifosfamide
  • [Number-of-references] 3
  •  go-up   go-down


55. Hosokawa Y, Saiki S, Hanafusa T, Meguro N, Maeda O, Kinouchi T, Kuroda M, Usami M, Kotake T: [A case of adult Wilms' tumor]. Hinyokika Kiyo; 2001 Sep;47(9):641-3
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of adult Wilms' tumor].
  • Wilms' tumor is very rarely found in adults and there are no established treatment guidelines for such tumors in adults.
  • Computed tomography scan revealed a large right renal mass with enlarged lymph nodes.
  • Angiography showed a hypovascular tumor.
  • She underwent right nephrectomy and resection of lymph node metastasis with a diagnosis of malignant renal tumor.
  • Histopathological examination revealed nephroblastoma with lymph node metastasis.
  • The disease was classified as stage III according to the National Wilms' Tumor Study classification.
  • The patient received adjuvant chemotherapy consisting of ifosfamide, cisplatin, and etoposide.
  • This protocol was selected because of the published poor results with the standard Wilms' tumor chemotherapeutic agents when used in adults.
  • She remained without tumor recurrence as of six months after surgery.
  • Development of better therapeutic approaches to adult Wilms' tumor is awaited.
  • [MeSH-major] Kidney Neoplasms / therapy. Wilms Tumor / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Ifosfamide. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Nephrectomy. Treatment Outcome

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11692602.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  • [Number-of-references] 12
  •  go-up   go-down


56. Vecchioli Scaldazza C, Giacomini G: [Repeated bladder metastases from renal cell carcinoma. Report of a case with particular attention to the use of immunomodulators]. Minerva Urol Nefrol; 2000 Dec;52(4):215-8
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Repeated bladder metastases from renal cell carcinoma. Report of a case with particular attention to the use of immunomodulators].
  • [Transliterated title] Ripetuta metastatizzazione vescicale da carcinoma a cellule renali (CCR). Descrizione del caso con particolare riguardo all'impiego degli immunomodulatori.
  • The case of repeated metastases of the bladder from renal cell carcinoma in a 59 year old male patient is presented.
  • Two years after nephrectomy the ureteral stump and the bladder were interested by two different metastases.
  • Afterwards, other nine metastases developed into the bladder during the following 12 months.
  • Bladder metastases ranged between 2 and 4 mm.
  • No other metastasis was discovered by MRI and skeletal scintigraphy.
  • Thirteen months after the first bladder metastasis, intracavitary Bacillus Calmette-Guerin was used.
  • No report was found in the literature about BCG in the treatment of superficial bladder metastases from renal cell carcinoma.
  • However 15 months from beginning of BCG treatment no metastasis developed from the bladder that now is disease-free after a follow-up of 19 months.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. BCG Vaccine / therapeutic use. Carcinoma, Renal Cell / drug therapy. Carcinoma, Renal Cell / secondary. Kidney Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / secondary

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11315333.001).
  • [ISSN] 0393-2249
  • [Journal-full-title] Minerva urologica e nefrologica = The Italian journal of urology and nephrology
  • [ISO-abbreviation] Minerva Urol Nefrol
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / BCG Vaccine
  •  go-up   go-down


57. Ivanyi P, Winkler T, Grosshennig A, Reuter C, Merseburger AS, Ganser A, Grünwald V: Treatment with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma is associated with drug-induced hyperparathyroidism: a single center experience in 59 patients. World J Urol; 2010 Jun;28(3):311-7
Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma is associated with drug-induced hyperparathyroidism: a single center experience in 59 patients.
  • PURPOSE: Multi-targeted tyrosine kinase inhibitors (MTKIs) are the standard in the treatment of metastatic renal cell carcinoma (mRCC).
  • Demographics, chemistry, parathyroid and renal function, bone metastasis and clinics were assessed, retrospectively.
  • Parathyroid hormone (PTH), calcium and phosphate were either determined prior to, during or after cessation of MTKI therapy.
  • RESULTS: From evaluable patients, 90% (N = 53) received at least one MTKI treatment, 10% (N = 8) had evaluations without MTKI exposure.
  • The mean PTH value prior to MTKI treatment was 49.4 (range (r):2.5-115), increased during the therapy to 121.2 (r:5-302) (P = 0.003) and returned to its basic values after MTKI cessation.
  • In parallel, mean phosphate significantly decreased during the treatment from 1.10 (r = 0.66-1.59) to 0.87 (r = 0.48-1.45) (P < 0.001) and calcium showed a slight decrease (P = 0.039).
  • PTH alterations were associated with clinical signs in some patients but not with bone metastasis or renal function.
  • Univariate logistic regression analysis of pathologically elevated PTH levels revealed an association with MTKI treatment duration.
  • CONCLUSION: Even though the mechanism of bone mineral alteration remains elusive, the MTKI treatment is associated with a dysregulated parathyroid axis, which may have clinical implications in a number of patients.
  • Furthermore, prospective trials are mandatory, and PTH monitoring should be considered in selected patients during MTKI treatment.
  • [MeSH-major] Carcinoma, Renal Cell / drug therapy. Carcinoma, Renal Cell / secondary. Hyperparathyroidism / chemically induced. Kidney Neoplasms / drug therapy. Kidney Neoplasms / pathology. Protein Kinase Inhibitors / adverse effects
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Bone Density / drug effects. Calcium / metabolism. Cohort Studies. Confidence Intervals. Drug Delivery Systems. Female. Follow-Up Studies. Humans. Incidence. Kidney Function Tests. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Odds Ratio. Parathyroid Hormone / metabolism. Probability. Prognosis. Protein-Tyrosine Kinases / antagonists & inhibitors. Registries. Retrospective Studies. Risk Assessment. Survival Analysis

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dtsch Arztebl Int. 2008 Mar;105(13):232-7 [19629201.001]
  • [Cites] J Bone Miner Res. 2007 Nov;22(11):1679-89 [17663639.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):12-9 [15671523.001]
  • [Cites] N Engl J Med. 2006 May 11;354(19):2006-13 [16687713.001]
  • [Cites] Br J Haematol. 2004 May;125(4):420 [15142112.001]
  • [Cites] N Engl J Med. 2005 Dec 8;353(23):2477-90 [16339096.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):185-7 [17215538.001]
  • [Cites] N Engl J Med. 2006 Aug 10;355(6):628; author reply 628-9 [16903020.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] Nat Med. 2006 Aug;12(8):908-16 [16862153.001]
  • [Cites] Onkologie. 2009 Mar;32(3):129-38 [19295254.001]
  • [Cites] Ann Oncol. 2008 Sep;19(9):1613-8 [18436521.001]
  • [Cites] N Engl J Med. 2006 Dec 7;355(23):2494-5 [17151376.001]
  • [Cites] World J Urol. 2005 Jul;23(3):202-12 [15812574.001]
  • [Cites] Nephron. 1976;16(1):31-41 [1244564.001]
  • [Cites] Cancer. 2005 Dec 1;104(11):2323-33 [16240452.001]
  • [Cites] Lancet. 2009 Jul 11;374(9684):145-58 [19595349.001]
  • [Cites] J Clin Oncol. 2008 Nov 10;26(32):5204-12 [18838713.001]
  • [Cites] N Engl J Med. 2006 Aug 10;355(6):627; author reply 628-9 [16899786.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Apr;94(4):1131-6 [19174494.001]
  • (PMID = 20443009.001).
  • [ISSN] 1433-8726
  • [Journal-full-title] World journal of urology
  • [ISO-abbreviation] World J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Parathyroid Hormone; 0 / Protein Kinase Inhibitors; EC 2.7.10.1 / Protein-Tyrosine Kinases; SY7Q814VUP / Calcium
  •  go-up   go-down


58. Marec-Bérard P, Crassard N, Schell M, Philip T, Thiesse P, Ranchin B, Frappaz D: Osteosarcoma metastatic to the kidney and iatrogenic hemorrhage. Pediatr Blood Cancer; 2008 Mar;50(3):690-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteosarcoma metastatic to the kidney and iatrogenic hemorrhage.
  • A 16-year old female presented painful masses in the lumbar region 5 years after the initial diagnosis of a localized osteosarcoma of the tibia.
  • A bone scan confirmed an increased uptake in the renal areas.
  • An ultrasound-guided fine needle biopsy confirmed the diagnosis of metastases.
  • The procedure was complicated by subcapsular hemorrhage and gross hematuria.
  • Renal metastases from osteosarcoma are usually asymptomatic and invisible on abdominal X-rays.
  • The diagnosis is generally established by radionuclide bone scan or abdominal CT-scan.
  • Our observation suggests that histological documentation of these unusual clinical presentations should be carefully weighed against the risk of the procedure.
  • [MeSH-major] Biopsy, Fine-Needle / adverse effects. Bone Neoplasms / surgery. Hemorrhage / etiology. Kidney Neoplasms / secondary. Osteosarcoma / secondary. Tibia
  • [MeSH-minor] Amputation. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Calcinosis / etiology. Calcinosis / radiography. Camptothecin / analogs & derivatives. Camptothecin / therapeutic use. Child. Combined Modality Therapy. Doxorubicin / administration & dosage. Fatal Outcome. Female. Hematuria / etiology. Humans. Iatrogenic Disease. Ilium / pathology. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Methotrexate / administration & dosage. Ultrasonography, Interventional

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bleeding.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17226847.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 7673326042 / irinotecan; 80168379AG / Doxorubicin; XT3Z54Z28A / Camptothecin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


59. Schuster JM, Grady MS: Medical management and adjuvant therapies in spinal metastatic disease. Neurosurg Focus; 2001 Dec 15;11(6):e3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medical management and adjuvant therapies in spinal metastatic disease.
  • Metastatic spinal tumors are an increasingly common and difficult problem encountered by neurosurgeons and orthopedic surgeons.
  • To improve therapies and increase life expectancy for patients with tumors such as those of the breast and prostate, a global, systematic approach is required to maximize the preservation of neurological function, maintenance of spinal stability, and relief of pain, all with the ultimate goal of improved functional capacity and quality of life (QOL).
  • Although radiotherapy and surgery are still the primary therapeutic options, several new adjuvant therapies initially implemented to control pain more effectively have also been shown to reduce overall skeleton-related complications (pathological fractures and hypercalcemia) and may ultimately improve and extend QOL.
  • This more global approach to spinal metastases also includes optimizing each patient's overall medical condition and potential for healing (that is, nutrition), as well as avoiding potential complications associated with metastatic disease (such as deep vein thrombosis), including excessive blood loss in the case of renal metastasis.
  • A thorough knowledge and understanding of these therapeutic adjuvants is required to optimize care and to respond to our increasingly medically knowledgable patient population whose access to prevalent medical information has been increased because of the internet.
  • [MeSH-major] Spinal Neoplasms / secondary. Spinal Neoplasms / therapy
  • [MeSH-minor] Analgesics / therapeutic use. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Diphosphonates / therapeutic use. Embolization, Therapeutic. Fractures, Spontaneous / drug therapy. Fractures, Spontaneous / etiology. Fractures, Spontaneous / prevention & control. Humans. Hypercalcemia / drug therapy. Hypercalcemia / etiology. Pain / drug therapy. Pain / etiology. Postoperative Complications. Quality of Life. Radiopharmaceuticals / therapeutic use. Radiotherapy, Adjuvant. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16463995.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics; 0 / Antineoplastic Agents; 0 / Diphosphonates; 0 / Radiopharmaceuticals
  • [Number-of-references] 28
  •  go-up   go-down


60. Kai H, Yamagata K, Usui J, Shimizu Y, Hirayama A, Yoh K, Mase K, Hirayama K, Nagase S, Nagata M, Kawai K, Akaza H, Koyama A: Crescentic glomerulonephritis associated with renal cell carcinoma after cancer immunotherapy. J Nephrol; 2005 Jul-Aug;18(4):436-41
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Crescentic glomerulonephritis associated with renal cell carcinoma after cancer immunotherapy.
  • A 59 year-old woman showed rapidly progressive glomerulonephritis during immunotherapy for metastatic renal cell carcinoma.
  • She received unilateral nephrectomy and cytotoxic T lymphocyte (CTL) therapy for the treatment of retroperitoneal lymph node metastasis of renal cell carcinoma.
  • With CTL therapy, her retroperitoneal lymph node mass decreased in size.
  • One year after the third round of CTL therapy, her serum creatinine was increased and massive proteinuria occurred.
  • Her renal biopsy specimen revealed necrotizing and crescentic glomerulonephritis with immune complex deposition.
  • Consequently, for the purpose of avoiding interfering with the CTL therapy, we performed double filtration plasmapheresis (DFPP) monotherapy for removal of immune complexes without using immunosuppressive drugs or prednisolone.
  • After 24 sessions of DFPP, her serum IgG was reduced from 3,942 mg/dL to 2,400 mg/dL, and proteinuria (from 9.0 g/day to 0.9 g/day) and renal function (serum creatinine; from 5.6 mg/dL to 2.2 mg/dL) also improved.
  • The autopsy sample of the kidney showed that most of the glomeruli were obsolescent, but immunoglobulin depositions were reduced and necrotizing lesions were diminished.
  • In the patients with RPGN associated with renal cell carcinoma, renal functional recovery has not been observed upon immunosuppressive treatment.
  • We also discuss previous reports of RPGN associated with renal cell carcinoma, or RPGN after cancer immunotherapy.
  • [MeSH-major] Carcinoma, Renal Cell / drug therapy. Glomerulonephritis / chemically induced. Immunologic Factors / adverse effects. Interferon-alpha / adverse effects. Kidney Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Glomerulonephritis.
  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16245250.001).
  • [ISSN] 1121-8428
  • [Journal-full-title] Journal of nephrology
  • [ISO-abbreviation] J. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Immunologic Factors; 0 / Interferon-alpha
  •  go-up   go-down


61. Lutterbach J, Pagenstecher A, Weyerbrock A, Schultze-Seemann W, Waller CF: Early-stage penile carcinoma metastasizing to brain: case report and literature review. Urology; 2005 Aug;66(2):432
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Early-stage penile squamous cell carcinoma with subsequent distant metastases is rare.
  • Further in the disease course, the patient developed metastases in the kidney, adrenal gland, retroperitoneal lymph nodes, lung, and brain.
  • He underwent multiple resections, whole brain radiotherapy, and several chemotherapy regimens.
  • All these metastases were histologically confirmed.
  • Forty months after the first diagnosis, the patient died of thromboembolic complications.
  • [MeSH-major] Brain Neoplasms / secondary. Carcinoma, Squamous Cell / secondary. Penile Neoplasms / pathology
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Male. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16098372.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


62. Sier CF, Gelderman KA, Prins FA, Gorter A: Beta-glucan enhanced killing of renal cell carcinoma micrometastases by monoclonal antibody G250 directed complement activation. Int J Cancer; 2004 May 10;109(6):900-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beta-glucan enhanced killing of renal cell carcinoma micrometastases by monoclonal antibody G250 directed complement activation.
  • Metastases from renal cell carcinomas (RCC) are resistant to radiation and chemotherapy but are relatively immunogenic.
  • In vivo, bi-MAb may be more effective as therapeutic agent due to its increased C5a generating properties.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibody-Dependent Cell Cytotoxicity / immunology. Carcinoma, Renal Cell / therapy. Complement Activation / immunology. Glucans / pharmacology. Kidney Neoplasms / therapy
  • [MeSH-minor] Antigens, CD3 / immunology. Apoptosis. Complement System Proteins / physiology. Cytotoxicity, Immunologic. Enzyme-Linked Immunosorbent Assay. Flow Cytometry. Humans. Microscopy, Fluorescence. Spheroids, Cellular / immunology. Spheroids, Cellular / metabolism. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • (PMID = 15027124.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD3; 0 / G250 monoclonal antibody; 0 / Glucans; 9007-36-7 / Complement System Proteins
  •  go-up   go-down


63. Alves A, Adam R, Majno P, Delvart V, Azoulay D, Castaing D, Bismuth H: Hepatic resection for metastatic renal tumors: is it worthwhile? Ann Surg Oncol; 2003 Jul;10(6):705-10
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic resection for metastatic renal tumors: is it worthwhile?
  • BACKGROUND: Liver metastases of malignant renal tumors are regarded as having an ominous prognosis because they are infrequently amenable to radical surgery and respond poorly to chemotherapy.
  • Little is known of the outcome of isolated metastases to the liver for which resection is potentially curative.
  • METHODS: Data on 14 patients with liver metastases from renal tumors who underwent a liver resection in a single center between 1982 and 2001 were analyzed retrospectively.
  • The curative pattern of hepatectomy (2-year survival, 69% vs. 0%; P =.001), an interval between the nephrectomy and the diagnosis of liver metastases in excess of 24 months (2-year survival, 71% vs. 25%; P =.05), tumor size <50 mm (2-year survival, 83% vs. 17%; P =.006), and the possibility of achieving a repeat hepatectomy in the case of recurrence (2-year survival, 100% vs. 21%; P =.02) were associated with a better outcome after the liver resection.
  • CONCLUSIONS: In patients with liver metastases of malignant renal tumors, an aggressive policy for achieving tumor eradication seems to offer a chance for long-term survival, especially after a long disease-free interval from the nephrectomy.
  • However, despite an aggressive policy for achieving tumor eradication, recurrence frequently occurs after liver resection.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Carcinoma, Renal Cell / surgery. Kidney Neoplasms / pathology. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Sarcoma / secondary. Sarcoma / surgery. Wilms Tumor / secondary. Wilms Tumor / surgery

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12839857.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Zeng H, Li X, Yao J, Zhu Y, Liu J, Yang Y, Qiang W: Multifocal brain metastases in clear cell renal cell carcinoma with complete response to sunitinib. Urol Int; 2009;83(4):482-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multifocal brain metastases in clear cell renal cell carcinoma with complete response to sunitinib.
  • We report the case of a 70-year-old man who received sunitinib treatment for brain metastatic clear cell renal cell carcinoma.
  • After 6 months of treatment, brain MRI showed complete disappearance of two brain metastases.
  • To the best of our knowledge, this is the first reported case of multifocal brain metastases in renal cell carcinoma with complete response to sunitinib.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Carcinoma, Renal Cell / drug therapy. Carcinoma, Renal Cell / secondary. Indoles / therapeutic use. Kidney Neoplasms / pathology. Pyrroles / therapeutic use


65. Miwa S, Mizokami A, Konaka H, Izumi K, Nohara T, Namiki M: A case of bone, lung, pleural and liver metastases from renal cell carcinoma which responded remarkably well to zoledronic acid monotherapy. Jpn J Clin Oncol; 2009 Nov;39(11):745-50
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of bone, lung, pleural and liver metastases from renal cell carcinoma which responded remarkably well to zoledronic acid monotherapy.
  • Herein, we report a rare case in which bisphosphonate zoledronic acid (ZA) effectively treated not only multiple bone metastases but also lung, pleural and liver metastases from renal cell carcinoma (RCC).
  • Recently, ZA is used to treat skeletal-related events (SREs) such as bone pain caused by bone metastasis from many kinds of cancer.
  • The patient in the present report had multiple bone metastases from RCC.
  • Remarkable improvement of the bone metastasis was observed following treatment with ZA at a dosage of 4 mg administered once every 4 weeks.
  • Moreover, lung, pleural and liver metastases also diminished markedly in size in response to the treatment.
  • The metastases have shown no progression for 20 months since starting the ZA treatment.
  • We believe that the present report is the first of its kind announcing that ZA monotherapy has been effective for lung, pleural and liver metastases from RCC.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bone Density Conservation Agents / therapeutic use. Bone Neoplasms / drug therapy. Carcinoma, Renal Cell / secondary. Diphosphonates / therapeutic use. Imidazoles / therapeutic use. Kidney Neoplasms / pathology. Liver Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Pleural Neoplasms / drug therapy
  • [MeSH-minor] Adult. Humans. Male. Tomography, X-Ray Computed. Treatment Outcome


66. Dokmak S, Cabral C, Couvelard A, Aussilhou B, Belghiti J, Sauvanet A: Pancreatic metastasis from nephroblastoma: an unusual entity. JOP; 2009;10(4):396-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic metastasis from nephroblastoma: an unusual entity.
  • CONTEXT: Pancreatic metastasis from renal cell carcinoma is a well-known entity.
  • When metastatic disease is limited to the pancreas, pancreatic resection is the optimal treatment.
  • A nephroblastoma is a frequent childhood cancer but can also occur in adults.
  • A metastatic nephroblastoma mainly affects the lung and the liver.
  • Pancreatic metastases from a nephroblastoma are very rare.
  • CASE REPORT: We report an extremely rare case of pancreatic metastases in a 20-year-old man who had a right nephroblastoma resected at 9 years of age and liver metastases treated by right hepatectomy at 18 years of age.
  • Pancreatic metastasis was revealed by acute pancreatitis.
  • Surgical resection was performed without preoperative chemotherapy because the patient was symptomatic and had already received numerous chemotherapy protocols.
  • Pathological examination confirmed pancreatic and liver metastases from a nephroblastoma composed of blastematous cells mixed with embryonic tubular structures without lymph node metastases.
  • After resection, the patient received adjuvant high dose chemotherapy with autologous hematopoietic stem-cell support.
  • CONCLUSION: This is probably the first case of pancreatic metastasis from a nephroblastoma reported in a living patient.
  • A nephroblastoma, like clear cell renal carcinoma, can be considered a possible etiology of pancreatic metastasis from a primary renal tumor.
  • [MeSH-major] Kidney Neoplasms / pathology. Pancreatic Neoplasms / secondary. Wilms Tumor / pathology
  • [MeSH-minor] Combined Modality Therapy. Drug Therapy / methods. Humans. Male. Pancreaticoduodenectomy / methods. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19581742.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


67. Schenk JP, Graf N, Günther P, Ley S, Göppl M, Kulozik A, Rohrschneider WK, Tröger J: Role of MRI in the management of patients with nephroblastoma. Eur Radiol; 2008 Apr;18(4):683-91
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Magnetic resonance imaging (MRI) presents the main diagnostic tool for differentiation and staging of renal tumors in childhood.
  • Nephroblastoma is the most common malignant tumor in children.
  • Radiological findings play an important role in therapy study trials of SIOP (International Society of Pediatric Oncology), especially for indicating preoperative chemotherapy.
  • In the past few years MRI has gained great importance in imaging of nephroblastoma and has replaced computed tomography (CT).
  • The aim of this review is to present the diagnostic possibilities of MRI in relation to the requirements of therapy studies.
  • For nephroblastoma, MRI provides important information about tumor extent and distant metastasis.
  • A special focus of MRI in distant staging is venous extent of the tumor into the inferior vena cava.
  • In addition, MRI has an important role in monitoring chemotherapy and in preoperative planning by volume rendering and three-dimensional postprocessing.
  • [MeSH-major] Kidney Neoplasms / diagnosis. Magnetic Resonance Imaging / methods. Wilms Tumor / diagnosis
  • [MeSH-minor] Child. Contrast Media. Humans. Image Interpretation, Computer-Assisted. Imaging, Three-Dimensional. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 2001 Jan;192(1):63-8; quiz 146 [11192924.001]
  • [Cites] Rofo. 2006 Jan;178(1):38-45 [16392056.001]
  • [Cites] Pediatr Radiol. 1994;24(2):85-7 [8078728.001]
  • [Cites] Pediatr Radiol. 2005 Aug;35(8):766-73 [15864576.001]
  • [Cites] Radiographics. 2004 Sep-Oct;24(5):1317-30 [15371611.001]
  • [Cites] Pediatr Radiol. 2004 Aug;34(8):660-4 [15103425.001]
  • [Cites] Radiologe. 2005 Dec;45(12 ):1112-23 [16151729.001]
  • [Cites] AJR Am J Roentgenol. 2001 Jul;177(1):229-36 [11418435.001]
  • [Cites] Langenbecks Arch Chir Suppl Kongressbd. 1996;113:1078-83 [9101785.001]
  • [Cites] Klin Padiatr. 2004 May-Jun;216(3):132-40 [15175957.001]
  • [Cites] Med Pediatr Oncol. 2000 Mar;34(3):183-90 [10696124.001]
  • [Cites] Radiologe. 2001 May;41(5):418-26 [11405103.001]
  • [Cites] J Urol. 2003 Sep;170(3):939-42; discussion 943-4 [12913746.001]
  • [Cites] Pediatr Pathol. 1990;10(1-2):1-36 [2156243.001]
  • [Cites] Radiographics. 1998 Jul-Aug;18(4):947-68 [9672980.001]
  • [Cites] Eur J Pediatr Surg. 2004 Oct;14(5):316-21 [15543480.001]
  • [Cites] Rofo. 2004 Oct;176(10):1447-52 [15383976.001]
  • [Cites] J Pediatr Surg. 1998 Feb;33(2):165-70 [9498380.001]
  • [Cites] Rofo. 2005 Oct;177(10):1373-9 [16170706.001]
  • [Cites] Pediatr Radiol. 2006 Oct;36(10):1075-81 [16896692.001]
  • [Cites] J Pediatr Surg. 2005 Feb;40(2):364-70 [15750930.001]
  • [Cites] Radiology. 1993 Aug;188(2):517-21 [8392214.001]
  • [Cites] Rofo. 2005 Jun;177(6):800-4 [15902628.001]
  • [Cites] Vestn Rentgenol Radiol. 2001 Nov-Dec;(6):29-43 [11858031.001]
  • [Cites] Pediatr Radiol. 1998 Jun;28(6):435-43 [9634458.001]
  • [Cites] Br J Urol. 1996 Nov;78(5):772-6 [8976777.001]
  • [Cites] Magn Reson Imaging Clin N Am. 2002 May;10(2):275-302 [12424947.001]
  • [Cites] Urol Clin North Am. 2000 Aug;27(3):443-54 [10985144.001]
  • [Cites] J Pediatr Surg. 1991 Jan;26(1):64-7 [1848614.001]
  • (PMID = 18193429.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 30
  •  go-up   go-down


68. Avnet S, Cenni E, Perut F, Granchi D, Brandi ML, Giunti A, Baldini N: Interferon-alpha inhibits in vitro osteoclast differentiation and renal cell carcinoma-induced angiogenesis. Int J Oncol; 2007 Feb;30(2):469-76
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interferon-alpha inhibits in vitro osteoclast differentiation and renal cell carcinoma-induced angiogenesis.
  • Bone is a common site of osteolytic and richly vascularized metastases of renal cell carcinoma (RCC) and Interferon (IFN)-alpha based therapies have been considered for the treatment of patients affected by this disease.
  • The effects of IFN-alpha on metastatic RCC patients have been related to its immunomodulatory, and cytotoxic activity on tumor cells, but there could be an effect also on tumor induced osteoclast differentiation and bone angiogenesis.
  • When osteoclasts obtained from human peripheral blood mononuclear cells, cultured in the presence of receptor activator of nuclear factor-kappaB (RANKL) and macrophage-colony stimulating factor (M-CSF), were treated with IFN-alpha, the expression of bone tartrate resistant acid phosphatase (TRACP) type 5b was reduced, as well as calcium-phosphate resorption activity and expression of pro-osteoclatic transcription factor c-Fos.
  • These data demonstrate multiple activities of IFN-alpha on renal cancer-induced bone disease, in addition to its recognized role as a cytotoxic and immunomodulatory agent, because they indicate its ability to reduce bone resorption and to impair tumor-associated angiogenesis, and they also suggest the use of IFN-alpha to treat skeletal metastases of other carcinomas.
  • [MeSH-major] Angiogenesis Inhibitors / pharmacology. Carcinoma, Renal Cell / metabolism. Interferon-alpha / physiology. Kidney Neoplasms / metabolism. Neovascularization, Pathologic. Osteoclasts / metabolism
  • [MeSH-minor] Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Cell Differentiation. Chemotaxis. Disease Progression. Fibroblast Growth Factor 2 / biosynthesis. Fibroblast Growth Factor 2 / metabolism. Fibroblasts / metabolism. Humans. Macrophages / metabolism. Neoplasm Metastasis. Proto-Oncogene Proteins c-fos / metabolism. Time Factors. Vascular Endothelial Growth Factor A / metabolism

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17203230.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Interferon-alpha; 0 / Proto-Oncogene Proteins c-fos; 0 / Vascular Endothelial Growth Factor A; 103107-01-3 / Fibroblast Growth Factor 2
  •  go-up   go-down


69. Akaza H, Tsukamoto T, Onishi T, Miki T, Kinouchi T, Naito S: A low-dose combination therapy of interleukin-2 and interferon-alpha is effective for lung metastasis of renal cell carcinoma: a multicenter open study. Int J Clin Oncol; 2006 Dec;11(6):434-40
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A low-dose combination therapy of interleukin-2 and interferon-alpha is effective for lung metastasis of renal cell carcinoma: a multicenter open study.
  • BACKGROUND: To confirm the usefulness of a combination therapy of interleukin-2 (IL-2) and interferon-alpha (IFN-alpha) against metastatic renal cell carcinoma, the recommended dose of IFN-alpha to use in combination with low-dose IL-2 was determined (phase 1).
  • CONCLUSION: In the 46 patients evaluated in phase 1 and phase 2, the response rate was 26.1% (12/46), being highest in 38.7% (12/31) of those who were nephrectomized, and with only lung metastases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Renal Cell / drug therapy. Kidney Neoplasms / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adult. Aged. Carcinoma / drug therapy. Carcinoma / secondary. Female. Humans. Interferon-alpha / administration & dosage. Interleukin-2 / administration & dosage. Male. Middle Aged. Pilot Projects. Survival Rate

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1999 Feb;5(2):281-9 [10037176.001]
  • [Cites] Biometrics. 1982 Mar;38(1):143-51 [7082756.001]
  • [Cites] Urol Clin North Am. 1993 May;20(2):283-95 [7684167.001]
  • [Cites] J Clin Oncol. 2005 Feb 10;23(5):965-72 [15613696.001]
  • [Cites] J Urol. 1989 Nov;142(5):1173-80 [2478725.001]
  • [Cites] Cancer. 1997 Oct 1;80(7):1198-220 [9317170.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):688-96 [7884429.001]
  • [Cites] N Engl J Med. 1998 Apr 30;338(18):1272-8 [9562581.001]
  • [Cites] Nihon Hinyokika Gakkai Zasshi. 1992 Apr;83(4):447-72 [1593826.001]
  • [Cites] Biochem J. 1985 Jul 15;229(2):429-39 [3899106.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):16-24 [16330672.001]
  • [Cites] Cancer. 1986 Sep 15;58(6):1231-5 [3742449.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3987-94 [14581421.001]
  • (PMID = 17180511.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Interleukin-2
  •  go-up   go-down


70. Hirshberg B, Cochran C, Skarulis MC, Libutti SK, Alexander HR, Wood BJ, Chang R, Kleiner DE, Gorden P: Malignant insulinoma: spectrum of unusual clinical features. Cancer; 2005 Jul 15;104(2):264-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant insulinoma: spectrum of unusual clinical features.
  • BACKGROUND: Malignant insulinoma occurs in a few patients with insulinoma.
  • Due to the small sample of patients, there are little data regarding their clinical manifestation as well as the preferred treatment modalities.
  • METHODS: The authors identified 10 patients with metastatic insulinoma.
  • First, four patients presented with lymph node metastasis and, after surgical excision, maintained a prolonged tumor-free survival.
  • Second, four patients presented with metastatic disease to the liver, which appeared years after the initial diagnosis and presumed curative surgery.
  • Various treatment modalities were used to control hypoglycemia.
  • Less successful modalities included radiofrequency ablation, radical debulking surgery, verapamil therapy, octreotide therapy, and chemotherapy.
  • CONCLUSIONS: The current study, as well as others, suggested that metastatic insulinoma may have a variable natural history.
  • After the initial surgical resection, the biology of the tumor, rather than any treatment modality, was most likely the major determinant of long-term survival.
  • [MeSH-minor] Adult. Aged. Female. Humans. Hypoglycemia / etiology. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Metastasis. Time Factors

  • Genetic Alliance. consumer health - Insulinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2000 Oct;85(10):3628-30 [11061513.001]
  • [Cites] Cancer Invest. 1999;17(7):474-8 [10518191.001]
  • [Cites] South Med J. 2004 Feb;97(2):199-201 [14982275.001]
  • [Cites] J Endocrinol Invest. 1992 Jul-Aug;15(7):543-7 [1447492.001]
  • [Cites] Dig Dis Sci. 1989 Mar;34(3 Suppl):28S-39S [2537716.001]
  • [Cites] Surg Clin North Am. 2001 Jun;81(3):527-42 [11459269.001]
  • [Cites] N Engl J Med. 1980 Nov 20;303(21):1189-94 [6252466.001]
  • [Cites] J R Soc Med. 2001 Jul;94(7):349-50 [11418708.001]
  • [Cites] Cardiovasc Intervent Radiol. 1995 Nov-Dec;18(6):353-9 [8591620.001]
  • [Cites] Am J Clin Oncol. 1989 Dec;12(6):498-501 [2556011.001]
  • [Cites] Ann Intern Med. 1995 Aug 15;123(4):269-73 [7611592.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Sep;85(9):3222-6 [10999812.001]
  • [Cites] Exp Clin Endocrinol. 1990 Feb;95(1):77-82 [2159401.001]
  • [Cites] J Hepatol. 2001 Sep;35(3):421-30 [11592607.001]
  • [Cites] Drug Intell Clin Pharm. 1988 Feb;22(2):136-8 [2894965.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2000 Feb;12(2):151-7 [10741928.001]
  • [Cites] Ann Intern Med. 1984 Feb;100(2):233-5 [6318634.001]
  • [Cites] Endocr Pathol. 2001 Fall;12(3):351-4 [11740056.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Apr;56(4):557-9 [11966750.001]
  • [Cites] Surgery. 1992 Dec;112(6):1024-31; discussion 1031-2 [1455305.001]
  • [Cites] Mayo Clin Proc. 1991 Jul;66(7):711-9 [1677058.001]
  • [Cites] Surgery. 2002 Dec;132(6):976-82; discussion 982-3 [12490844.001]
  • [Cites] Postgrad Med J. 1997 Oct;73(864):640-1 [9497974.001]
  • [Cites] Ann Intern Med. 1989 Jan 1;110(1):35-50 [2535688.001]
  • [Cites] S Afr Med J. 1988 Jul 16;74(2):75-6 [2899913.001]
  • [Cites] Tumori. 2000 Nov-Dec;86(6):475-9 [11218190.001]
  • [Cites] J Vasc Interv Radiol. 1999 Apr;10(4):397-403 [10229465.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Oct;80(10):2884-7 [7559869.001]
  • [Cites] J Nucl Med. 2003 Oct;44(10 ):1556-60 [14530466.001]
  • [Cites] Surgery. 1984 Dec;96(6):1027-37 [6095477.001]
  • [Cites] World J Surg. 1992 Jul-Aug;16(4):632-9 [1357829.001]
  • [Cites] J Gastroenterol. 1998 Dec;33(6):891-4 [9853567.001]
  • [Cites] J Gastroenterol. 1997 Dec;32(6):830-5 [9430026.001]
  • [Cites] Ann Intern Med. 1973 Aug;79(2):239-57 [4147411.001]
  • [Cites] Am J Clin Pathol. 1990 Feb;93(2):273-6 [1689098.001]
  • [Cites] Surg Today. 1995;25(7):640-2 [7549277.001]
  • [Cites] J Am Coll Surg. 1999 Oct;189(4):368-73 [10509462.001]
  • [Cites] Korean J Intern Med. 2003 Mar;18(1):45-9 [12760268.001]
  • [Cites] Ann Intern Med. 1990 Sep 1;113(5):404-6 [2382921.001]
  • (PMID = 15937909.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 CL999999
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 39
  • [Other-IDs] NLM/ NIHMS425894; NLM/ PMC4136659
  •  go-up   go-down


71. Nishikimi T, Ishida R, Yamada H, Yokoi K, Kobayashi H, Obata K: [A case of multiple lung metastases and cervical lymph node metastasis of renal cell carcinoma failing to respond to interferon-alpha (IFN-alpha) but markedly responding to interleukin-2 (IL-2)]. Nihon Hinyokika Gakkai Zasshi; 2004 Jan;95(1):54-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of multiple lung metastases and cervical lymph node metastasis of renal cell carcinoma failing to respond to interferon-alpha (IFN-alpha) but markedly responding to interleukin-2 (IL-2)].
  • A 59-year-old man was admitted to our hospital with a left renal mass.
  • A tumor was removed by radical nephrectomy and histological examination revealed renal cell carcinoma (pT2 N0 V1a).
  • Two years later, CT scan showed multiple lung metastases.
  • Despite treatment with recombinant IFN-alpha 2b, 5-FU, and MMC, the disease showed slow progression.
  • About three years after the start of combination therapy, cervical lymph node metastasis appeared.
  • Intravenous IL-2 therapy was started at a low daily dose of 35 x 10(4) JRU, and the daily dose was increased to 140 x 10(4) JRU.
  • Because of side effect, the dose was subsequently decreased to 70 x 10(4) JRU three times per week.
  • After 31 weeks of IL-2 therapy, his multiple lung metastases and cervical lymph node metastasis disappeared.
  • The patient's natural killer cell (NK) activity and Lymphokine activated killer cell (LAK) activity were low before IL-2 therapy, but both NK activity and LAK activity showed a marked increase after IL-2 therapy started.
  • Therefore, the tumor response to IL-2 was suggested to depend on NK activity and LAK activity.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Renal Cell / drug therapy. Interleukin-2 / therapeutic use. Kidney Neoplasms / drug therapy. Lung Neoplasms / secondary. Lymph Nodes / pathology
  • [MeSH-minor] Drug Administration Schedule. Humans. Interferon-alpha / administration & dosage. Lymphatic Metastasis. Male. Middle Aged. Neck. Quality of Life. Recombinant Proteins. Tomography, X-Ray Computed. Treatment Failure

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14978942.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Interleukin-2; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


72. Kreher U, Darius J, Wien F: Establishing individual metabolite patterns for patients on valproate therapy. Eur J Drug Metab Pharmacokinet; 2001 Jan-Jun;26(1-2):99-107
Hazardous Substances Data Bank. VALPROIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishing individual metabolite patterns for patients on valproate therapy.
  • Therefore, integrating different kinds of co-medication into a single polytherapy group seemed to be inadequate.
  • An adult patient on VPA monotherapy, suffering form intrahepatic metastasis and renal insufficiency, showed an extremely altered metabolic pattern, with the 4-ene and the omega-/omega1-metabolites being strongly elevated and the major beta-metabolites (E)-2-ene and (E,E)-2,3'-diene being significantly diminished.
  • We suggest determining the individual metabolic profile, consisting of accessible major and minor metabolites, for every patient when VPA therapy has been started or been modified.
  • [MeSH-major] Anticonvulsants / pharmacokinetics. Anticonvulsants / therapeutic use. Epilepsy / drug therapy. Epilepsy / metabolism. Valproic Acid / pharmacokinetics. Valproic Acid / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Biotransformation. Child. Child, Preschool. Drug Interactions. Female. Gas Chromatography-Mass Spectrometry. Humans. Infant. Male

  • MedlinePlus Health Information. consumer health - Epilepsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurology. 1987 Mar;37(3):379-85 [3102998.001]
  • [Cites] Epilepsy Res. 1996 Oct;25(2):107-12 [8884168.001]
  • [Cites] Hepatology. 1982 Sep-Oct;2(5):591-7 [6811394.001]
  • [Cites] Epilepsia. 1988 Sep-Oct;29(5):530-42 [3137017.001]
  • [Cites] Xenobiotica. 1984 May;14(5):375-87 [6433565.001]
  • [Cites] Eur J Clin Pharmacol. 1987;32(2):219-22 [3108013.001]
  • [Cites] Epilepsia. 2000 Feb;41(2):222-30 [10691121.001]
  • [Cites] J Chromatogr B Biomed Appl. 1996 Jun 28;682(1):67-72 [8832426.001]
  • [Cites] Chem Res Toxicol. 1988 Jul-Aug;1(4):195-9 [2979731.001]
  • [Cites] Hepatology. 1984 Nov-Dec;4(6):1153-8 [6437961.001]
  • [Cites] Brain Dev. 1983;5(3):334-7 [6412580.001]
  • [Cites] Epilepsia. 1992 Jan-Feb;33(1):165-71 [1733752.001]
  • [Cites] Epilepsia. 1993 Mar-Apr;34(2):332-46 [8453944.001]
  • [Cites] Clin Pharmacol Ther. 1990 Sep;48(3):225-35 [2119269.001]
  • [Cites] J Pharmacol Exp Ther. 1996 Jun;277(3):1305-14 [8667191.001]
  • [Cites] Science. 1987 Feb 20;235(4791):890-3 [3101178.001]
  • [Cites] Pharm Weekbl Sci. 1992 Jun 19;14(3A):108-13 [1502008.001]
  • [Cites] Drug Metab Dispos. 1985 Jan-Feb;13(1):81-96 [2858383.001]
  • [Cites] Biochemistry. 1983 Apr 12;22(8):1827-32 [6133549.001]
  • [Cites] Schweiz Med Wochenschr. 1991 Feb 16;121(7):228-33 [2008603.001]
  • [Cites] J Pediatr. 1979 Jul;95(1):142-4 [383927.001]
  • [Cites] Epilepsia. 1994 Sep-Oct;35(5):1005-15 [7925143.001]
  • [Cites] Epilepsia. 1992 Jul-Aug;33(4):736-42 [1628592.001]
  • [Cites] J Pharm Pharmacol. 2000 Sep;52(9):1043-7 [11045883.001]
  • [Cites] Hepatology. 1984 Nov-Dec;4(6):1143-52 [6437960.001]
  • [Cites] Neurology. 1989 Feb;39(2 Pt 1):201-7 [2492646.001]
  • [Cites] Eur J Pediatr. 1983 Oct;141(1):30-5 [6416845.001]
  • [Cites] Br J Clin Pharmacol. 1990 Jan;29(1):116-9 [2105099.001]
  • [Cites] Epilepsy Res. 2000 Oct;41(3):259-68 [10962217.001]
  • [Cites] Med Toxicol Adverse Drug Exp. 1988 Mar-Apr;3(2):85-106 [3131628.001]
  • [Cites] Epilepsia. 1988 Sep-Oct;29(5):543-7 [3137018.001]
  • [Cites] Pediatr Res. 1975 Mar;9(3):133-8 [1121419.001]
  • [Cites] Hepatology. 1982 Sep-Oct;2(5):648-9 [6811395.001]
  • [Cites] J Clin Pharmacol. 1983 Apr;23(4):178-85 [6408143.001]
  • [Cites] Epilepsia. 1999 Jul;40(7):1036-40 [10403231.001]
  • [Cites] Br J Clin Pharmacol. 1989 Mar;27(3):323-8 [2497766.001]
  • [Cites] Neurology. 1996 Feb;46(2):465-9 [8614514.001]
  • [Cites] Brain Dev. 1992 May;14(3):178-81 [1514659.001]
  • (PMID = 11554442.001).
  • [ISSN] 0378-7966
  • [Journal-full-title] European journal of drug metabolism and pharmacokinetics
  • [ISO-abbreviation] Eur J Drug Metab Pharmacokinet
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anticonvulsants; 614OI1Z5WI / Valproic Acid
  •  go-up   go-down


73. Matsuda R, Motoyama Y, Takeshima Y, Kimura R, Iida J, Nakamura M, Mishima H, Park YS, Hirabayashi H, Nakase H, Sakai T: [A case of brain metastasis of renal pelvic carcinoma]. No Shinkei Geka; 2009 Feb;37(2):179-82
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of brain metastasis of renal pelvic carcinoma].
  • Contrast-enhanced computed tomography (CT) revealed renal tumor and multiple lung metastases.
  • After nephroureterectomy, combination chemotherapy consisting of methotrexate, doxorubicin and cisplatin was performed.
  • Contrast-enhanced CT of the head revealed a heterogeneous enhancement tumor in the parietal lobe.
  • Because the tumor was invasive in the superior sagittal sinus, subtotal removal of the tumor was performed.
  • Pathological examination indicated transitional cell carcinoma the same feature as in the renal pelvis.
  • She returned to ordinary life, but 7 months later tumor recurrence took place.
  • Repeated surgical resection and stereotactic radiosurgery was performed, but she died 44 months after the initial nephroureterectomy due to the relapse of brain metastasis.
  • Brain metastasis of renal pelvic carcinoma is extremely rare, and we have found only three case reports.
  • We describe the course of our patient, and review the three cases of brain metastasis of renal pelvic carcinoma that are in the literature.
  • [MeSH-major] Brain Neoplasms / secondary. Carcinoma, Transitional Cell / pathology. Kidney Neoplasms / pathology. Kidney Pelvis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19227160.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 11
  •  go-up   go-down


74. Kijima T, Fujii Y, Suyama T, Okubo Y, Yonese J, Fukui I: Lung and bone metastases from renal cell carcinoma responsive to bisphosphonates: a case report. Int J Urol; 2008 Jun;15(6):546-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung and bone metastases from renal cell carcinoma responsive to bisphosphonates: a case report.
  • Bisphosphonates (BP) are inhibitors of bone-resorption and have become the current standard of care for preventing skeletal complications associated with bone metastases.
  • We report a renal cell carcinoma case in which multiple lung and bone metastases displayed remarkable remission to BP therapy using 30 mg pamidronate once, 4 mg zoledronate once, and weekly 10 mg incadronate 10 times for 3 months.
  • This is the first case report to demonstrate that BP therapy is effective to non-osseous visceral metastasis as well as bone metastases in the clinical setting.
  • [MeSH-major] Bone Density Conservation Agents / therapeutic use. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Carcinoma, Renal Cell / drug therapy. Carcinoma, Renal Cell / secondary. Diphosphonates / therapeutic use. Imidazoles / therapeutic use. Kidney Neoplasms / pathology. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18489646.001).
  • [ISSN] 1442-2042
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphonates; 0 / Imidazoles; 138330-18-4 / cimadronate; 6XC1PAD3KF / zoledronic acid; OYY3447OMC / pamidronate
  •  go-up   go-down


75. Weber K, Doucet M, Kominsky S: Renal cell carcinoma bone metastasis--elucidating the molecular targets. Cancer Metastasis Rev; 2007 Dec;26(3-4):691-704
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal cell carcinoma bone metastasis--elucidating the molecular targets.
  • The development of bone metastasis from renal cell carcinoma (RCC) signals a transition to a terminal state for the patient with previously isolated disease.
  • These patients may suffer the morbidity of severe, persistent pain, pathologic fractures, and spinal compression from vertebral metastasis before they succumb to their cancer.
  • Although recent advancements have been made in the understanding of breast and prostate bone metastasis, there has been less knowledge in the area of metastatic RCC to the skeleton.
  • This particular cancer in bone remains relatively resistant to standard forms of treatment such as radiation and chemotherapy.
  • A better understanding of the biology of RCC bone metastasis is critically needed in order to improve treatment.
  • Bone-derived cell lines and an experimental animal model have been developed in order to explore the relevant mechanisms of how RCC cells survive within and destroy the bone.
  • [MeSH-major] Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology
  • [MeSH-minor] Animals. Diphosphonates / therapeutic use. Disease Models, Animal. Humans. Interleukin-6 / physiology. Mice. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, Epidermal Growth Factor / physiology. Signal Transduction. Transforming Growth Factor beta / physiology


76. Giacosa R, Santi R, Vaglio A, Pavone L, Ferrozzi F, Passalacqua R, Buzio C: "Late" regressions of metastases from renal cancer after a period of disease progression continuing the same intermittent low dose immunotherapy regimen. Acta Biomed; 2004 Aug;75(2):126-30
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] "Late" regressions of metastases from renal cancer after a period of disease progression continuing the same intermittent low dose immunotherapy regimen.
  • We here describe two patients with metastatic renal cell cancer (mRCC) treated with immunotherapy in whom the metastases completely regressed after a period of progressive disease.
  • The treatment schedule was based on repeated cycles of low-dose recombinant interleukin-2 and recombinant interferon-alpha, and was never changed during the course of the disease.
  • The first patient received immunotherapy because of multiple bilateral lung metastases.
  • Progressive disease, with mediastinal lymph node involvement and an increased number of lung metastases, was observed after 30 months of regularly repeated therapy; complete regression was achieved after 60 months of immunotherapy (after 16 immunotherapy cycles).
  • The second patient began immunotherapy because of three small lung metastases.
  • Long-term low-dose immunotherapy may bring about an effective anti-tumour response even late in the course of the disease and after an initial disease progression.
  • [MeSH-major] Adenocarcinoma, Clear Cell / secondary. Carcinoma, Renal Cell / secondary. Immunologic Factors / therapeutic use. Interferon-alpha / therapeutic use. Interleukin-2 / therapeutic use. Kidney Neoplasms / pathology. Lung Neoplasms / secondary
  • [MeSH-minor] Combined Modality Therapy. Disease Progression. Drug Administration Schedule. Drug Therapy, Combination. Fatal Outcome. Heart Neoplasms / complications. Heart Neoplasms / secondary. Humans. Immunotherapy. Male. Middle Aged. Nephrectomy. Recombinant Proteins / administration & dosage. Recombinant Proteins / therapeutic use. Remission Induction. Shock, Cardiogenic / etiology. Time Factors

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15481703.001).
  • [ISSN] 0392-4203
  • [Journal-full-title] Acta bio-medica : Atenei Parmensis
  • [ISO-abbreviation] Acta Biomed
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Immunologic Factors; 0 / Interferon-alpha; 0 / Interleukin-2; 0 / Recombinant Proteins
  •  go-up   go-down


77. Oya M, Murai M: Renal cell carcinoma: relevance of pathology. Curr Opin Urol; 2003 Nov;13(6):445-9
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal cell carcinoma: relevance of pathology.
  • PURPOSE OF REVIEW: Although pathological findings including tumour grade and tumour-node-metastasis stage provide prognostic information, the outcome for patients with renal cell carcinoma is occasionally unpredictable.
  • Many studies have been undertaken to improve prediction of the prognosis of renal cell carcinoma, along with efforts to clarify the pathogenesis of renal cell carcinoma at the molecular level.
  • This article reviews the advances in renal cell carcinoma research relevant to pathology published between 1 May 2002 and 30 April 2003.
  • RECENT FINDINGS: The establishment of a strict tumour grading system or adding microscopic venous invasion or tumour necrosis is potentially useful for predicting patient outcomes.
  • Tumour development in renal cell carcinoma can be considered as accumulating heterogenous molecular events related to cytokine production, cell cycle control, anti-apoptotic signal machinery and angiogenesis.
  • SUMMARY: Finding the target genes related to the von Hippel-Lindau pathway may explain the resistance of chemotherapy, and also provide a clue to finding a novel therapeutic option.
  • Molecular targeting therapy can be applicable after more general molecules leading to tumour development and the metastasis of renal cell carcinoma have been identified.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Genetic Markers. Kidney Neoplasms / pathology. Neoplasm Staging

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14560136.001).
  • [ISSN] 0963-0643
  • [Journal-full-title] Current opinion in urology
  • [ISO-abbreviation] Curr Opin Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers
  • [Number-of-references] 36
  •  go-up   go-down


78. Hillard VH, Musunuru K, Hasan I, Zia S, Hirschfeld A: Long-term management of bilateral metastases of renal cell carcinoma to the choroid plexus. Acta Neurochir (Wien); 2003 Sep;145(9):793-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term management of bilateral metastases of renal cell carcinoma to the choroid plexus.
  • BACKGROUND: Metastatic tumors to the brain presenting exclusively in the choroid plexus are exceedingly rare.
  • These events are frequently associated with renal cell carcinoma (RCC), of which all reported cases have been solitary lesions.
  • METHODS: The authors present the unusual case of a patient with metastatic RCC who developed bilateral tumors of the choroid plexus.
  • These tumors, one of which was confirmed to be metastatic RCC by histologic analysis, were treated over a 5-year period with a combination of interventions, including surgical resection, stereotactic radiosurgery, and chemotherapy, in conjunction with continual radiological monitoring.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Carcinoma, Renal Cell / therapy. Choroid Plexus Neoplasms / secondary. Choroid Plexus Neoplasms / therapy. Kidney Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Middle Aged. Time Factors


79. Cotellese R, Noccioli P, Francione T, Angelucci D, Zappacosta R, Napolitano L: [Thyroid metastasis from renal carcinoma. Clinical case]. Chir Ital; 2002 Nov-Dec;54(6):861-7
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Thyroid metastasis from renal carcinoma. Clinical case].
  • [Transliterated title] Metastasi tiroidea da carcinoma renale. Caso clinico.
  • Metastatic thyroid tumours are uncommon among reported clinical cases, but are more frequent in autopsy series.
  • The most common sites of the primary tumours are the breast (21%), kidney (12%) and lung (11%) and in some cases are detected only at autopsy.
  • The clinical presence of thyroid tumefaction, whether associated or not with compressive symptoms, in a patient with a history of surgical treatment for renal cell carcinoma should lead to the suspicion of a metastatic nodule.
  • Total thyroidectomy, whether associated or not with radiation therapy, is the procedure of choice in these cases, when possible, above all in the presence of regional symptoms.
  • In spite of treatment, however, the prognosis of metastatic disease is very poor.
  • Therapeutic measures allow a mean survival of 34 months in the various reported series.
  • The authors report the case of a 66-year-old female patient who had undergone left-side nephrectomy for a renal cell carcinoma 7 years earlier.
  • Ultrasonography of the thyroid gland and fine needle aspiration cytology showed malignant features.
  • Subsequently, total thyroidectomy was performed and the histological examination revealed that the nodule was composed of tumour cells with abundant clear cytoplasm and round nuclei; with the characteristics of the renal cell carcinoma resected 7 years previously.
  • Since computed tomography revealed secondaries in the lungs, the patient is still being managed with chemotherapy, with arrest of the metastatic progression, and is in a fairly good clinical condition.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology. Thyroid Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12613336.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 26
  •  go-up   go-down


80. Isaka T, Nakagawa H, Yamada J, Suzuki T, Wada K: Intraoperative ultrasonographically guided direct ethanol injection for a brain metastasis from renal cell carcinoma: case report. Neurosurg Rev; 2001 Jul;24(2-3):123-6
Hazardous Substances Data Bank. ETHANOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative ultrasonographically guided direct ethanol injection for a brain metastasis from renal cell carcinoma: case report.
  • A 60-year-old man presented with a brain metastasis from renal cell carcinoma (RCC).
  • Computer tomography revealed a homogeneously enhanced tumor, 3.0 cm in maximum diameter, in the right medial temporal lobe.
  • Cerebral angiography revealed that the tumor was mainly fed by the right posterior cerebral artery.
  • After craniotomy, under ultrasonography (US) guidance, a total of 3.0 ml of ethanol was injected into the tumor to diminish the intratumoral vascular flow.
  • After a marked decrease in the vascular flow, the tumor was totally removed using piecemeal technique.
  • During surgery, only minimal bleeding from the tumor was noted.
  • In conclusion, this can be a safe, easy, and effective therapeutic technique for diminishing vascular flow within brain tumors rich in vascularity, such as brain metastases from RCC.
  • [MeSH-major] Brain Neoplasms / therapy. Brain Neoplasms / ultrasonography. Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / therapy. Ethanol / therapeutic use. Kidney Neoplasms / pathology
  • [MeSH-minor] Cerebrovascular Circulation / drug effects. Humans. Injections, Intralesional. Intraoperative Care. Male. Middle Aged

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11485233.001).
  • [ISSN] 0344-5607
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 3K9958V90M / Ethanol
  •  go-up   go-down


81. Hensiek AE, Kellerman AJ, Hill JT: Spontaneous regression of a solitary cerebral metastases in renal carcinoma followed by meningioma development under medroxyprogesterone acetate therapy. Br J Neurosurg; 2000 Aug;14(4):354-6
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous regression of a solitary cerebral metastases in renal carcinoma followed by meningioma development under medroxyprogesterone acetate therapy.
  • A case of regression of a probable cerebral metastasis of a hypernephroma after nephrectomy and hormone therapy is presented.
  • The patient subsequently developed a meningioma after therapy with medroxyprogesterone acetate.
  • A relationship between meningioma growth and sex hormones has been documented, but little is known about the effect of hormone therapies on tumour growth.
  • [MeSH-major] Brain Neoplasms / secondary. Carcinoma, Renal Cell / secondary. Kidney Neoplasms / drug therapy. Meningioma / chemically induced. Neoplasm Regression, Spontaneous. Neoplasms, Second Primary / chemically induced

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11045205.001).
  • [ISSN] 0268-8697
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; C2QI4IOI2G / Medroxyprogesterone Acetate
  •  go-up   go-down


82. Tosco L, Palazzetti A, Crivellaro S, Guaitoli P, Abbinante M, Frea B: [Batson's paravertebral venous plexus and single vertebral metastases from renal cell carcinoma]. Urologia; 2010 Jan-Mar;77 Suppl 16:42-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Batson's paravertebral venous plexus and single vertebral metastases from renal cell carcinoma].
  • OBJECTIVES: The presence of a single site bone metastasis in patients with renal cell carcinoma (RCC) is a rare clinical event.
  • We report a single case of RCC with solitary vertebral metastasis and review of literature about renal tumor spreading in order to understand the anatomic explanation for this peculiar clinical case.
  • RESULTS: There are rare cases of single vertebral metastasis from RCC and these are characterized from a contemporary neoplastic thrombus.
  • CONCLUSION: Enrolment of para-vertebral Batson's venous system could have a major role in the RCC vertebral metastatic diffusion.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology. Lumbar Vertebrae / pathology. Spinal Neoplasms / secondary
  • [MeSH-minor] Adrenal Gland Neoplasms / drug therapy. Adrenal Gland Neoplasms / secondary. Chemotherapy, Adjuvant. Decompression, Surgical. Humans. Indoles / therapeutic use. Interferons / therapeutic use. Low Back Pain / etiology. Magnetic Resonance Imaging. Male. Middle Aged. Neoplastic Cells, Circulating. Nephrectomy. Psoas Muscles / pathology. Pyrroles / therapeutic use. Radiography. Radiotherapy, Adjuvant. Sciatica / etiology. Veins

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21104661.001).
  • [ISSN] 1724-6075
  • [Journal-full-title] Urologia
  • [ISO-abbreviation] Urologia
  • [Language] ita
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Indoles; 0 / Pyrroles; 9008-11-1 / Interferons; V99T50803M / sunitinib
  •  go-up   go-down


83. Hasegawa Y, Mita K, Matsubara A, Ohdan H: Multidisciplinary treatment including sorafenib stabilized the bone metastases of renal cell carcinoma in an immunosuppressed renal transplant recipient. Int J Clin Oncol; 2009 Oct;14(5):465-7
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidisciplinary treatment including sorafenib stabilized the bone metastases of renal cell carcinoma in an immunosuppressed renal transplant recipient.
  • We report a case of metastatic renal cell carcinoma in the native kidney of a renal transplant recipient.
  • The patient was a 57-year-old man in whom a tumor in the native kidney and bone metastasis were found incidentally on imaging, 10 years after cadaveric renal transplantation.
  • Interferon-alpha was administered after nephrectomy and following palliative irradiation of the metastasis, but could not be continued because of allograft dysfunction.
  • This is the first reported case of sorafenib administration to a renal transplant recipient with metastatic renal cell carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Carcinoma, Renal Cell / drug therapy. Immunosuppressive Agents / therapeutic use. Kidney Neoplasms / therapy. Kidney Transplantation
  • [MeSH-minor] Benzenesulfonates / administration & dosage. Bone Density Conservation Agents / administration & dosage. Diphosphonates / administration & dosage. Humans. Imidazoles / administration & dosage. Incidental Findings. Interferon-alpha / adverse effects. Male. Middle Aged. Nephrectomy. Niacinamide / analogs & derivatives. Phenylurea Compounds. Protein Kinase Inhibitors / therapeutic use. Pyridines / administration & dosage. Radiotherapy, Adjuvant. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7099-109 [15466206.001]
  • [Cites] Oncologist. 2007 Apr;12(4):426-37 [17470685.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3150-7 [12915606.001]
  • [Cites] Transplantation. 1998 Aug 27;66(4):471-6 [9734490.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):962-9 [12942563.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] Kidney Int. 2003 Mar;63(3):1130-6 [12631097.001]
  • [Cites] J Hepatol. 2003 Nov;39(5):875-8 [14568274.001]
  • [Cites] J Urol. 1994 Sep;152(3):943-5 [8051761.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):251-7 [15593084.001]
  • [Cites] J Urol. 1997 Jul;158(1):42-4 [9186319.001]
  • [Cites] Eur Urol. 2007 Jun;51(6):1502-10 [17408850.001]
  • [Cites] Br J Urol. 1995 May;75(5):572-7 [7613790.001]
  • [Cites] BJU Int. 2006 Aug;98(2):298-302 [16879668.001]
  • [Cites] Eur Urol. 1982;8(6):340-2 [6183119.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jan 1;34(1):251-66 [12118559.001]
  • [Cites] Urologe A. 1997 Mar;36(2):126-9 [9199039.001]
  • [Cites] Urology. 2007 Mar;69(3):462-4 [17382145.001]
  • (PMID = 19856059.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Benzenesulfonates; 0 / Bone Density Conservation Agents; 0 / Diphosphonates; 0 / Imidazoles; 0 / Immunosuppressive Agents; 0 / Interferon-alpha; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 6XC1PAD3KF / zoledronic acid; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


84. Morimoto H, Tsuzaka Y, Kaneko T, Matsushima H, Homma Y: [Tegafur-uracil markedly reduced pulmonary metastasis from renal cell carcinoma refractory to sorafenib, interferon and interleukin 2]. Gan To Kagaku Ryoho; 2010 Oct;37(10):2007-10
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tegafur-uracil markedly reduced pulmonary metastasis from renal cell carcinoma refractory to sorafenib, interferon and interleukin 2].
  • In September 2003, a 68-year-old man was with renal cell carcinoma(RCC)underwent left radical nephrectomy.
  • The pathological diagnosis was renal cell carcinoma, clear cell type, grade 1, pT3bNxMx stage III.
  • Seventeen months later, lung metastasis was detected by CT and treated with recombinant interferon(IFN) -α2b (Intron A®) 600×10⁴ units until the regrowth lung metastasis in May, 2008.
  • Sorafenib, an antiangiogenic molecular-targeted agent, at a dose of 800 mg per day, was administered as the second time treatment.
  • Nevertheless, it was discontinued in 2 months because of an increase in tumor size, severe hand-foot syndrome and thrombocytopenia.
  • Therefore, the treatment was switched to natural human IFNa with tegafur-uracil at 300 mg per day since February 2009.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Renal Cell / drug therapy. Drug Resistance, Neoplasm. Kidney Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Tegafur / therapeutic use. Uracil / therapeutic use
  • [MeSH-minor] Aged. Benzenesulfonates / administration & dosage. Benzenesulfonates / therapeutic use. Humans. Interferons / administration & dosage. Interferons / therapeutic use. Interleukin-2 / administration & dosage. Interleukin-2 / therapeutic use. Male. Niacinamide / analogs & derivatives. Phenylurea Compounds. Pyridines / administration & dosage. Pyridines / therapeutic use. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20948275.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Benzenesulfonates; 0 / Interleukin-2; 0 / Phenylurea Compounds; 0 / Pyridines; 1548R74NSZ / Tegafur; 25X51I8RD4 / Niacinamide; 56HH86ZVCT / Uracil; 9008-11-1 / Interferons; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


85. Kramer CK, Ferreira N, Silveiro SP, Gross JL, Dora JM, Azevedo MJ: Pituitary gland metastasis from renal cell carcinoma presented as a non-functioning macroadenoma. Arq Bras Endocrinol Metabol; 2010;54(5):498-501
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pituitary gland metastasis from renal cell carcinoma presented as a non-functioning macroadenoma.
  • Metastatic tumors involving the pituitary gland are an uncommon finding and occur in up to 1% of all pituitary tumor resections.
  • Five years ago, he underwent a right radical nephrectomy for renal cell carcinoma, followed by chemotherapy and radiotherapy for lung and parotid metastases.
  • The patient underwent a transsphenoidal tumor resection that revealed renal cell carcinoma.
  • This case illustrates that metastatic pituitary lesions can mimic typical symptoms and signs of pituitary macroadenoma.
  • Furthermore, clinical diabetes insipidus, a common finding of pituitary metastases, can be absent.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology. Pituitary Neoplasms / secondary
  • [MeSH-minor] Adenoma / diagnosis. Aged. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20694412.001).
  • [ISSN] 1677-9487
  • [Journal-full-title] Arquivos brasileiros de endocrinologia e metabologia
  • [ISO-abbreviation] Arq Bras Endocrinol Metabol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


86. Cannizzaro MA, Veroux M, Cavallaro A, Costanzo M, Galasso MG, Veroux PF: [Skin metastasis from renal carcinoma: epidemiologic and clinical features]. Ann Ital Chir; 2002 May-Jun;73(3):305-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Skin metastasis from renal carcinoma: epidemiologic and clinical features].
  • [Transliterated title] Metastasi cutanee da carcinoma renale: aspetti epidemiologici e clinici.
  • The Authors present an additional case of a 70-years old male patient with skin metastasis from renal cell carcinoma, 15 months after nephrectomy.
  • Skin metastasis affect 3-6% of patients with renal cell carcinoma.
  • The surgical treatment is mandatory for single nodule.
  • Chemotherapy is often ineffectual.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology. Skin Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12404898.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


87. Muraishi Y, Mitani N, Fuse H, Saiki I: Effect of a matrix metalloproteinase inhibitor (ONO-4817) on lung metastasis of murine renal cell carcinoma. Anticancer Res; 2001 Nov-Dec;21(6A):3845-52
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of a matrix metalloproteinase inhibitor (ONO-4817) on lung metastasis of murine renal cell carcinoma.
  • We examined the anti-metastatic effect of a newly developed inhibitor of synthetic matrix metalloproteinase (MMP), ONO-4817, on experimental pulmonary metastasis of murine renal cell carcinoma (Renca) cells and on tumor cell invasion, through reconstituted basement membrane (Matrigel) in vitro using the same cells.
  • Oral administration of ONO-4817 (50-200 mg/kg/day) to Renca-bearing mice resulted in a dose-dependent inhibition of lung metastasis without a loss of body weight.
  • We also found that oral administration of ONO-4817 significantly inhibited the angiogenic response (number of vessels oriented towards the tumor mass) and the growth of tumors inoculated i.d. in syngeneic mice.
  • In conclusion, ONO-4817 effectively inhibited lung metastasis of Renca cells through its anti-invasive and anti-angiogenic properties.
  • These results suggest that use of the MMP inhibitor (MMPI) ONO-481 7 may provide a therapeutic basis for preventing lung recurrence and metastasis of renal cell carcinoma.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinoma, Renal Cell / prevention & control. Carcinoma, Renal Cell / secondary. Kidney Neoplasms / drug therapy. Lung Neoplasms / prevention & control. Lung Neoplasms / secondary. Phenyl Ethers / pharmacology. Protease Inhibitors / pharmacology
  • [MeSH-minor] Animals. Cell Adhesion / drug effects. Cell Division / drug effects. Cell Movement / drug effects. Female. Matrix Metalloproteinase 2 / biosynthesis. Matrix Metalloproteinase 2 / metabolism. Matrix Metalloproteinase Inhibitors. Mice. Mice, Inbred BALB C. Neovascularization, Pathologic / prevention & control

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11911256.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Matrix Metalloproteinase Inhibitors; 0 / N-hydroxy-5-ethoxymethyloxy-2-methyl-4-(4-phenoxybenzoyl)aminopentanamide; 0 / Phenyl Ethers; 0 / Protease Inhibitors; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


88. Badar Q, Ali N, Abbasi N, Ashraf S, Karsan F, Hashmi R: Ewing's sarcoma/PNET of kidney in 13-year-old girl. J Pak Med Assoc; 2010 Apr;60(4):314-5
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ewing's sarcoma/PNET of kidney in 13-year-old girl.
  • Ewing's sarcoma is the second most common primary tumour of bone in childhood.
  • Less frequently it occurs in soft tissues.
  • Ewing's sarcoma/primitive neuroectodermal tumour (ES/PNET) is an extra ordinarily rare primary tumour in the kidney.
  • Only very few cases of primary renal Ewing's sarcoma have been reported in the literature to date.
  • We present a case of primary right renal Ewing's sarcoma in a 13-year-old girl who was diagnosed as a case of stage IV ES/PNET of kidney with metastases to lung and liver.
  • Right nephrectomy was done followed by adjuvant radiotherapy and chemotherapy with complete response to local and distant area.
  • [MeSH-major] Kidney Neoplasms / radiography. Neuroectodermal Tumors, Primitive / radiography. Sarcoma, Ewing / radiography
  • [MeSH-minor] Adolescent. Biopsy. Combined Modality Therapy. Diagnosis, Differential. Fatal Outcome. Female. Humans. Tomography, X-Ray Computed. Ultrasonography, Interventional

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20419980.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


89. Valcamonico F, Ferrari V, Amoroso V, Rangoni G, Simoncini E, Marpicati P, Vassalli L, Grisanti S, Marini G: Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma. J Neurooncol; 2009 Jan;91(1):47-50
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma.
  • We report the case of a 75-year old woman who received sorafenib (Nexavar), Bayer Pharmaceuticals Corporation, West Haven, CT) for a CNS relapse of clear cell renal cell carcinoma.
  • After four months of sorafenib treatment, a brain magnetic resonance imaging showed 95%-volumetric regression of cerebral metastasis.
  • To the best of our knowledge, this is the first almost complete resolution of brain metastases in renal cell carcinoma treated with sorafenib that has been described.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Pyridines / therapeutic use
  • [MeSH-minor] Aged. Cerebral Cortex / drug effects. Cerebral Cortex / pathology. Female. Humans. Magnetic Resonance Imaging. Niacinamide / analogs & derivatives. Phenylurea Compounds

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7099-109 [15466206.001]
  • [Cites] Oncologist. 2007 Apr;12(4):426-37 [17470685.001]
  • [Cites] Oncologist. 2007 Dec;12(12):1404-15 [18165617.001]
  • [Cites] N Engl J Med. 1996 Sep 19;335(12):865-75 [8778606.001]
  • [Cites] Ann Oncol. 2007 Jun;18 Suppl 6:vi22-5 [17591826.001]
  • [Cites] J Clin Oncol. 2004 Feb 1;22(3):454-63 [14752067.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2505-12 [16636341.001]
  • [Cites] J Urol. 2004 Mar;171(3):1071-6 [14767273.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2306-12 [17538177.001]
  • [Cites] Ann Oncol. 2007 Jul;18(7):1282-3 [17675397.001]
  • [Cites] Eur Urol. 2007 Jun;51(6):1741-3 [17126991.001]
  • (PMID = 18712279.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


90. Inoue T, Ohyama C, Hatakeyama S, Horikawa Y, Togashi H, Tsuchiya N, Matsuura S, Satoh S, Sato K, Habuchi T: [Active combination immunochemotherapy with interferon-alpha, interleukin-2 and gemcitabine for four patients with metastatic renal cell carcinoma]. Hinyokika Kiyo; 2005 Mar;51(3):165-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Active combination immunochemotherapy with interferon-alpha, interleukin-2 and gemcitabine for four patients with metastatic renal cell carcinoma].
  • Immunochemotherapy consisting of interferon-alpha (IFN-alpha), interleukin-2 (IL-2), and gemcitabine (GEM) for metastatic renal cell carcinoma.
  • A partial response maintained for 15 months, was obtained in one case resistant to IFN-alpha and IL-2 of para-aortic lymph node metastases (case 1).
  • A minor response with 30% reduction of lung metastasis was obtained in one IFN-alpha resistant case, and the duration was 6 months (case 2).
  • In one case, in contra-lateral renal metastasis, no disease progression was obtained for 6 months (case 3).
  • One case with resistance to IFN-alpha and IL-2, and who had preoperative abnormalities of corrected serum calcium, serum c-reactive protein and hemoglobin, had progressive disease and died of cancer after 6 months (case 4).
  • Although the response duration was short, the combination immunochemotherapy consisting of IFN-alpha, IL-2 and GEM may be a promising salvage regimen for the patients with metastatic renal cell carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Renal Cell / drug therapy. Deoxycytidine / analogs & derivatives. Immunotherapy. Kidney Neoplasms / drug therapy
  • [MeSH-minor] Adult. Drug Administration Schedule. Female. Humans. Interferon-alpha / administration & dosage. Interleukin-2 / administration & dosage. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15852669.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Interleukin-2; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


91. Rohrmann K, Schleypen J, Adam C, Hofstetter A, Siebels M: [Complete remission of pulmonary metastasis from renal cell carcinoma through inhalation therapy with Interleukin-2 after unsuccessful systemic immunochemotherapy]. Urologe A; 2004 Oct;43(10):1271-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Complete remission of pulmonary metastasis from renal cell carcinoma through inhalation therapy with Interleukin-2 after unsuccessful systemic immunochemotherapy].
  • [Transliterated title] Komplette Remission beim pulmonal metastasierten Nierenzellkarzinom durch Inhalationstherapie mit Interleukin-2 nach erfolgloser systemischer Immunchemotherapie.
  • Therapy of metastasized renal cell carcinoma is based on systemic immunotherapeutic strategies, if surgical resection is not possible.
  • The costs of inhalative Interleukin-2 therapy in case of pulmonary metastases as off-label-use are not accepted by compulsory health insurance yet.We report on a female patient with pulmonary metastasized renal cell carcinoma who had tumor progression after immunochemotherapy that followed complete response after inhalative therapy with Interleukin-2.
  • [MeSH-major] Carcinoma, Renal Cell / drug therapy. Carcinoma, Renal Cell / secondary. Interleukin-2 / administration & dosage. Kidney Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary
  • [MeSH-minor] Administration, Inhalation. Adult. Antineoplastic Agents / administration & dosage. Female. Humans. Immunotherapy / methods. Remission Induction / methods. Treatment Failure. Treatment Outcome

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1996 Jul;2(7):1115-22 [9816276.001]
  • [Cites] J Clin Oncol. 1999 Jul;17 (7):2039-43 [10561255.001]
  • [Cites] Urologe A. 2002 May;41(3):282-7 [12132280.001]
  • [Cites] Cancer. 2002 Sep 1;95(5):1045-50 [12209689.001]
  • [Cites] Cancer Immunol Immunother. 1993 Sep;37(4):213-9 [8348559.001]
  • [Cites] J Urol. 2003 Jun;169(6):2076-83 [12771723.001]
  • [Cites] Urologe A. 1997 Jan;36(1):45-9 [9123681.001]
  • [Cites] Int J Cancer. 2003 Oct 10;106(6):905-12 [12918068.001]
  • [Cites] Anticancer Res. 1999 Jul-Aug;19(4A):2679-83 [10470219.001]
  • [Cites] N Engl J Med. 1998 Apr 30;338(18):1272-8 [9562581.001]
  • [Cites] Cancer J Sci Am. 1997 Dec;3 Suppl 1:S98-105 [9457403.001]
  • [Cites] J Clin Oncol. 1992 Mar;10 (3):414-21 [1482425.001]
  • (PMID = 15372156.001).
  • [ISSN] 0340-2592
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interleukin-2
  •  go-up   go-down


92. Miyajima A, Kosaka T, Asano T, Asano T, Seta K, Kawai T, Hayakawa M: Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res; 2002 Aug 1;62(15):4176-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis.
  • Angiotensin II (AII) is a potent vasoconstrictor peptide from the renin-angiotensin system in the kidney.
  • The AII type 1 receptor (AT1R) is reportedly expressed in several tumors including renal cell carcinoma, and AII is involved in tumor angiogenesis.
  • We p.o. administered the long-acting AT1R antagonist, candesartan (10 mg/kg), to the 16 days mouse renal cancer lung metastasis model to test the preventive effects in tumor metastasis.
  • Pulmonary metastases of renal cancer showed prominent AT1R expression in both mice and humans, and candesartan treatment dramatically prevented lung metastatic nodules (14.9 +/- 1.8; P < 0.0001; n = 12) in mice along with the inhibition of neovascularization and vascular endothelial growth factor expression, compared with control metastatic mice (123.3 +/- 8.6; n = 13).
  • Candesartan is widely used clinically, so it seems to be a reasonable therapy for patients with lung metastases of renal cell carcinoma.
  • [MeSH-major] Angiotensin Receptor Antagonists. Antineoplastic Agents / pharmacology. Benzimidazoles / pharmacology. Kidney Neoplasms / drug therapy. Lung Neoplasms / prevention & control. Neovascularization, Pathologic / drug therapy. Tetrazoles / pharmacology
  • [MeSH-minor] Adult. Aged. Animals. Female. Humans. Male. Mice. Receptor, Angiotensin, Type 1. Receptors, Angiotensin / biosynthesis

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CANDESARTAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12154013.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiotensin Receptor Antagonists; 0 / Antineoplastic Agents; 0 / Benzimidazoles; 0 / Receptor, Angiotensin, Type 1; 0 / Receptors, Angiotensin; 0 / Tetrazoles; S8Q36MD2XX / candesartan
  •  go-up   go-down


93. Powis M: Neonatal renal tumours. Early Hum Dev; 2010 Oct;86(10):607-12
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neonatal renal tumours.
  • Neonatal renal tumours are rare, with only 7% of all neonatal tumours arising from the kidney.
  • Mesoblastic nephroma is the most common tumour to be found at this age, but Wilms' tumour and other malignant and benign tumours occur.
  • Given the low malignant potential of these tumours, treatment is by radical nephroureterctomy, except in cases with bilateral disease or syndromic patients with a high incidence of metachronous tumours.
  • Chemotherapy is rarely indicated.
  • Survival is generally excellent for all tumour types in this age group, the exception being malignant rhabdoid tumour of the kidney which may have metastases at presentation.
  • [MeSH-major] Kidney Neoplasms / diagnosis. Nephroma, Mesoblastic / diagnosis. Wilms Tumor / diagnosis
  • [MeSH-minor] Anatomy, Cross-Sectional. Diagnosis, Differential. Genetic Predisposition to Disease. Humans. Imaging, Three-Dimensional. Infant, Newborn. Neuroblastoma / diagnosis. Practice Guidelines as Topic. Risk Factors

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20888153.001).
  • [ISSN] 1872-6232
  • [Journal-full-title] Early human development
  • [ISO-abbreviation] Early Hum. Dev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  •  go-up   go-down


94. Kitasato A, Tajima Y, Kuroki T, Tsutsumi R, Tsuneoka N, Adachi T, Mishima T, Kanematsu T: Limited pancreatectomy for metastatic pancreatic tumors from renal cell carcinoma. Hepatogastroenterology; 2010 Mar-Apr;57(98):354-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limited pancreatectomy for metastatic pancreatic tumors from renal cell carcinoma.
  • BACKGROUND/AIMS: Metastasis of renal cell carcinoma (RCC) to distant organs occurs commonly, even after radical nephrectomy, but metastatic lesions are rarely detected in the pancreas.
  • The present study aim was to improve the postoperative quality of life of a patient with pancreatic metastasis of RCC through limited resection of the pancreas.
  • METHODOLOGY: Since therapeutic modalities including chemotherapy or radiation are ineffective for metastatic tumors, surgical intervention is a treatment of choice in selected patients.
  • In patients with multiple pancreatic metastases, however, near-total or total pancreatectomy may result in a lower quality of life postoperatively due to endocrine and exocrine pancreatic insufficiency.
  • RESULTS: We used limited resection of the pancreas combined with removal of the uncinate process and distal pancreatectomy for a 65-year-old woman with multifocal pancreatic metastases located in the uncinate process, body, and tail of the pancreas, which were detected 6 years after radical nephrectomy for RCC.
  • This surgical procedure allowed preservation of about 40% of the pancreatic parenchyma, with complete excision of metastatic tumors in the pancreas.
  • CONCLUSIONS: The patient has had an excellent quality of life with well-preserved pancreatic function and no evidence of tumor recurrence for 31 months after pancreatic surgery.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Carcinoma, Renal Cell / surgery. Kidney Neoplasms / pathology. Pancreatectomy / methods. Pancreatic Neoplasms / secondary. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Aged. Female. Humans. Neoplasm Staging. Nephrectomy. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20583442.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


95. Hara W, Tran P, Li G, Su Z, Puataweepong P, Adler JR Jr, Soltys SG, Chang SD, Gibbs IC: Cyberknife for brain metastases of malignant melanoma and renal cell carcinoma. Neurosurgery; 2009 Feb;64(2 Suppl):A26-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyberknife for brain metastases of malignant melanoma and renal cell carcinoma.
  • OBJECTIVE: To evaluate the efficacy of CyberKnife (Accuray, Inc., Sunnyvale, CA) stereotactic radiosurgery (SRS) for patients with brain metastases of malignant melanoma and renal cell carcinoma.
  • Sixty-two patients with 145 brain metastases of renal cell carcinoma or melanoma were identified.
  • Forty-four patients had malignant melanoma, and 18 patients had renal cell carcinoma.
  • Thirty-three patients had been treated systemically with either chemotherapy or immunotherapy, and 33 patients were taking corticosteroids at the time of treatment.
  • The mean tumor volume was 1.47 mL (range, 0.02-35.7 mL), and the mean prescribed dose was 20 Gy (range, 14-24 Gy).
  • Intracranial control was impacted by whole-brain radiotherapy (P = 0.01), previous chemotherapy (P = 0.01), and control of the primary at the time of SRS (P = 0.02).
  • Radiographic evidence of radiation necrosis developed in 4 patients (6%).
  • CONCLUSION: CyberKnife radiosurgery provided excellent local control with acceptable toxicity in patients with melanoma or renal cell brain metastases.
  • [MeSH-major] Brain Neoplasms / secondary. Brain Neoplasms / surgery. Carcinoma, Renal Cell / secondary. Melanoma / secondary. Radiosurgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Cranial Irradiation. Humans. Kaplan-Meier Estimate. Kidney Neoplasms / mortality. Kidney Neoplasms / pathology. Middle Aged. Retrospective Studies. Skin Neoplasms / mortality. Skin Neoplasms / pathology. Treatment Outcome


96. Murakami T, Komiya A, Mikata K, Kaneko S, Ikeda I: Cardiac metastasis of renal pelvic cancer. Int J Urol; 2007 Mar;14(3):240-1
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac metastasis of renal pelvic cancer.
  • Seven months previously he had undergone a laparoscopic left nephroureterectomy for a left renal pelvic tumor and was given two cycles of adjuvant chemotherapy (methotrexate, epirubicin and cisplatin).
  • On computed tomography, multiple lung tumors, as well as the right atrial and ventricular mass, were seen.
  • On autopsy, a right atrial and ventricular metastasis of the initial transitional cell carcinoma was found.
  • The patient's cause of death was acute heart failure as a result of cardiac metastasis of his initial renal pelvic carcinoma.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Heart Neoplasms / secondary. Kidney Neoplasms / pathology. Kidney Pelvis
  • [MeSH-minor] Aged. Diagnosis, Differential. Echocardiography. Fatal Outcome. Humans. Laparoscopy. Male. Nephrectomy / methods. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Kidney cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17430263.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


97. Umeda S, Ito K, Takahashi E, Kimura F, Sumitomo M, Kaji T, Hayakawa M, Asano T: [Clinical experience of treatment of liver metastasis of renal cell carcinoma treated with SMANCS/Lipiodol therapy]. Hinyokika Kiyo; 2010 Oct;56(10):543-9
Hazardous Substances Data Bank. Ethiodol .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical experience of treatment of liver metastasis of renal cell carcinoma treated with SMANCS/Lipiodol therapy].
  • The treatment for metastatic renal cell carcinoma (RCC) has changed dramatically after the beginning of molecular-targeted therapies.
  • However,the treatment for liver metastasis is still difficult in patients with metastatic RCC.
  • We treated liver metastases (8 target lesions) of RCC with stylene-maleic acid neocarzinostatin (SMANCS)/Lipiodol therapy.
  • At the treatment procedure,a catheter was inserted at the femoral artery (Seldinger's method),a microcatheter was selectively inserted into the branch of hepatic artery which fed the liver metastasis,and then SMANCS/Lipodol was infused.
  • We treated 1,2 and 1 patient 4,2, and 1 time,respectively.
  • Of 6 metastatic lesions which could be followed up for more than 6 months after the treatment,one had partial response for 4 months and 4 had stable disease for more than 6 months.
  • Four of the 6 lesions shrunk after SMANCS/Lipiodol treatment.
  • Two of 4 patients survived more than 18 months after the first SMANCS/Lipiodol therapy.
  • In all 9 SMANCS/Lipiodol treatments,grade 1 liver dysfunction (44.4%),ascites (11.1%) and fatigue (11.1%) occurred after the treatments.
  • These adverse events were all improved by conservative treatments.
  • SMANCS/Lipiodol therapy can be a treatment option as local treatment for liver metastasis of RCC.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Renal Cell / pathology. Ethiodized Oil / administration & dosage. Kidney Neoplasms / pathology. Liver Neoplasms / drug therapy. Maleic Anhydrides / administration & dosage. Polystyrenes / administration & dosage. Zinostatin / analogs & derivatives

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21063157.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Maleic Anhydrides; 0 / Polystyrenes; 0 / poly(maleic acid-styrene)neocarzinostatin; 8008-53-5 / Ethiodized Oil; 9014-02-2 / Zinostatin
  •  go-up   go-down


98. Saad F, Eastham JA: Zoledronic acid use in patients with bone metastases from renal cell carcinoma or bladder cancer. Semin Oncol; 2010 Jun;37 Suppl 1:S38-44
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Zoledronic acid use in patients with bone metastases from renal cell carcinoma or bladder cancer.
  • Approximately 30% of patients with renal cell carcinoma (RCC) and 40% of patients with bladder cancer develop bone metastases that can disrupt normal bone homeostasis and place patients at risk for potentially life-limiting skeletal-related events (SREs).
  • In the absence of bone-directed therapies, patients with RCC may experience up to four SREs per year.
  • In patients with bone metastases from RCC or bladder cancer, zoledronic acid (ZOL) significantly reduced the risk of SREs compared with placebo.
  • In addition to its bone-protective effects, preclinical and early clinical evidence indicates that ZOL prevents tumor progression.
  • For example, retrospective subset analysis in patients with RCC indicated that ZOL extended time to disease progression and demonstrated a trend toward improved overall survival compared with placebo.
  • Additionally, a study in patients with bone metastases from bladder cancer demonstrated that ZOL improved 1-year overall survival compared with placebo.
  • Bone metastases place a heavy burden on patients with RCC or bladder cancer, and early, continuous treatment with ZOL may provide anticancer benefits in addition to important patient quality of life.
  • [MeSH-major] Bone Neoplasms / prevention & control. Carcinoma, Renal Cell / drug therapy. Diphosphonates / therapeutic use. Imidazoles / therapeutic use. Kidney Neoplasms / drug therapy. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Bone Density Conservation Agents / therapeutic use. Disease Progression. Humans. Survival Analysis


99. Manuelli M, De Luca L, Iaria G, Tatangelo P, Sforza D, Perrone L, Bellini MI, Angelico R, Anselmo A, Tisone G: Conversion to rapamycin immunosuppression for malignancy after kidney transplantation. Transplant Proc; 2010 May;42(4):1314-6
Hazardous Substances Data Bank. SIROLIMUS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conversion to rapamycin immunosuppression for malignancy after kidney transplantation.
  • INTRODUCTION: Malignancies are a well-known complication of immunosuppressive therapy among renal transplant recipients, representing an important cause of long-term morbidity and mortality.
  • Rapamycin has been shown to limit the proliferation of a number of malignant cell lines in vivo and in vitro.
  • METHODS: Fifteen patients developed the following malignancies at a mean of 90.3 months (range = 10-252) after kidney transplantation: metastatic gastric cancer (n = 1), metastatic colon cancer (n = 1), bilateral nephrourothelioma (n = 1), skin cancer (n = 2), Kaposi's sarcoma (n = 2), posttransplant lymphoproliferative disorder (PTLD; n = 4), renal cell carcinoma T1 (n = 1), MALT lymphoma (n = 1), intramucous colon carcinoma (n = 1), liposarcoma of the spermatic cord (n = 1).
  • After the diagnosis of malignancy, the patients were switched from calcineurin inhibitor-based immunosuppression to rapamycin (monotherapy, n = 3), or associated with steroids (n = 6) or with mycophenolate mofetil (n = 6).
  • RESULTS: Both patients with metastatic cancer underwent chemotherapy but succumbed after 6 and 13 months.
  • Two patients with PTLD who underwent chemotherapy died after 12 and 36 months.
  • At a mean follow-up of 32.7 months (range = 7-56), the remaining 11 patients are cancer-free.
  • Renal graft function remained stable in all other patients from diagnosis throughout follow-up.
  • Nevertheless, it is difficult to assess whether tumor regression was due to rapamycin treatment or to the reduced immunosuppression.
  • [MeSH-major] Kidney Transplantation / immunology. Neoplasms / immunology. Sirolimus / therapeutic use
  • [MeSH-minor] Cell Division / drug effects. Cell Line, Tumor. Colonic Neoplasms / immunology. Colonic Neoplasms / pathology. Genital Neoplasms, Male / immunology. Genital Neoplasms, Male / pathology. Humans. Immunosuppression / methods. Immunosuppressive Agents / therapeutic use. Liposarcoma / immunology. Liposarcoma / pathology. Male. Neoplasm Metastasis. Skin Neoplasms / immunology. Skin Neoplasms / pathology. Stomach Neoplasms / immunology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010. Published by Elsevier Inc.
  • (PMID = 20534289.001).
  • [ISSN] 1873-2623
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


100. Fujiwara Y, Kiura K, Tabata M, Takigawa N, Hotta K, Umemura S, Omori M, Gemba K, Ueoka H, Tanimoto M: Remarkable shrinkage of sarcomatoid renal cell carcinoma with single-agent gemcitabine. Anticancer Drugs; 2008 Apr;19(4):431-3
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remarkable shrinkage of sarcomatoid renal cell carcinoma with single-agent gemcitabine.
  • Computed tomography showed a tumor in the left kidney and metastases in the left gluteus maximus muscle and lung.
  • The pathological diagnosis of a biopsy specimen obtained from a metastatic lesion in the left gluteus maximus muscle was sarcomatoid renal cell carcinoma.
  • This seriously ill patient suffering from advanced sarcomatoid renal cell carcinoma was treated with single-agent gemcitabine, resulting in symptom relief and a dramatic improvement in his status; all of the tumors had regressed significantly by the 11th dose of gemcitabine.
  • These findings indicate that single-agent gemcitabine is one of the few chemotherapeutic agents effective for palliation in patients with sarcomatoid renal cell carcinoma, even those with poor performance status.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Renal Cell / drug therapy. Deoxycytidine / analogs & derivatives. Kidney Neoplasms / drug therapy
  • [MeSH-minor] Buttocks / pathology. Humans. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Male. Middle Aged. Muscle Neoplasms / secondary. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18454054.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down






Advertisement